GOOG+0.33%
外观
2026-08-20 全球资产日报
- 数据时间：2026-08-20 10:01:32 Asia/Shanghai
- 报告类型：全球资产日报
重要新闻摘要
8 月 20 日凌晨公布的联储会议纪要保留进一步收紧政策的可能，并记录部分与会者对 AI 基础设施融资脆弱性和高估值资产重定价的担忧；利率市场当时给出的 9 月维持不变概率为 67.3%，加息 25 个基点概率为 32.7%。同一时段，美国财政部宣布自 9 月 9 日起把 10—30 年期国债回购规模提高至至少 40 亿美元，可能短期改善长债流动性；30 年期收益率此前触及 5.31%，财政可信度与期限溢价仍是反向力量。联储纪要转述，8 月 20 日、财政部回购，8 月 20 日、长端利率背景，8 月 19 日
伊朗相关风险继续支撑能源溢价。8 月 20 日早间消息称美国将扩大对伊朗制裁，布伦特 10 月合约收于 91.62 美元/桶；IEA 8 月月报把三季度全球石油供需缺口预测上修至 180 万桶/日。具体制裁文本、执行日期、实时船流和军事行动均未确认，因此当前证据支持通胀尾部与能源研究优先级，尚不足以确认新的供应中断幅度。制裁消息，8 月 20 日、布伦特收盘，8 月 20 日、IEA 8 月石油市场报告，8 月 12 日
AI 资本开支链出现更清晰的公司分化。
MRVL与 Google 的协议包含最多 5897 万股认股权，多数按每累计 5 亿美元合格收入归属；COHR2026 财年收入 71.2 亿美元，第四季度数据中心收入同比增长 66%。另一边，NBIS拟发行 45 亿美元可转优先票据并设置 6.75 亿美元增购选择权，常规时段下跌 9.87%；SMH在 5 日、20 日、60 日窗口分别落后SPY约 3.64、7.33、5.81 个百分点。订单和合作继续验证需求，融资条款、利润率与现金转换决定下一阶段胜负。MRVL与 Google，8 月 19 日、COHR财年结果，8 月 19 日、NBIS融资，8 月 19 日下周的验证窗口已经确定：
NVDA将于 8 月 26 日 17:00 ET 举行财报电话会，MRVL将于 8 月 27 日 13:45 PDT 举行电话会。NVDA此前给出的收入指引为 910 亿美元、上下浮动 2%，分析师平均预期约 919 亿美元；实际收入、毛利率、订单扩散和MRVL的合作收入节奏尚未公布。公开期权链缺少成交方向和本次 IBKR Greeks 收盘快照，事件风险不转换成具体期权策略。NVDA 财报安排、NVDA指引与预期，8 月 20 日、MRVL投资者日历8 月 19 日收盘的市场地图显示扩散已经越过少数大盘成长股：
RSP在 5 日、20 日、60 日窗口分别领先SPY0.89、1.51、4.36 个百分点，IWD三个窗口也领先，20 日成交量比为 1.537；XLV、XBI、XLE、XOP均有多窗口相对强度。医疗又得到事件验证：MRNA/MRK个体化 mRNA 疗法联合 Keytruda 的三期试验达到主要终点，RARE 和 REPL 分别获得 FDA 加速批准，但总生存期、确认性临床和商业化仍待验证。RSP 历史行情，8 月 19 日、XLV 历史行情，8 月 19 日、FDA 对 RARE 药物的公告，8 月 19 日、REPL 公告，8 月 6 日北京时间 8 月 20 日 10:01—10:08，
KOSPI上涨 6.53%，三星电子上涨 10.10%；上证综指上涨 0.59%。韩国市场的快速反弹为半导体风险偏好提供了盘中确认，A 股快照缺广度与板块数据，两地读数也不处于完全相同的时间截面，不能据此推断美股开盘后的持续性。KOSPI 实时快照、三星电子实时快照、上证综指快照Binance USDS-M 在北京时间 8 月 20 日 10:01 的快照中，
BTC、ETH、SOL约为 69720、2266.94、85.32 美元，24 小时分别上涨 8.35%、18.56%、11.17%，三者 Funding 均为正。8 月 19 日可见的BTC、ETH、SOLETF/ETP 净流量分别为 1.642 亿、1770 万和 250 万美元；报告日新一日流量尚未出现。单一交易所的价格与 Funding 可以证明反弹和多头付费，不能单独证明跨场所趋势或追加杠杆的胜率。BTCBinance 快照，发布时间不可用、BTC ETF 流量、ETH ETF 流量、SOL ETF 流量
观点
长端缓冲不足以解除高久期资产的估值约束
市场在交易两个相反方向：财政部回购改善长债流动性，联储的通胀反应函数、油价与财政期限溢价继续抬高贴现率尾部。我的判断是回购更可能缓和波动，尚不能改写高久期资产的风险预算。今天回避新增宽泛成长仓和杠杆半导体仓，不参与 SOXL 的事件前反弹；已有高质量经营证据的个股按公司事实处理，不做行业一刀切。
若美国 10 年、30 年期收益率在回购安排落地后连续回落，布伦特同时跌回事件溢价前区间，且下一轮通胀与就业数据没有重新强化加息路径，可以恢复高久期新增预算。若制裁执行、通航或库存数据把油价推向新高，或长端收益率重新突破近期高点，当前回避判断加强。下一次验证看回购后的期限溢价、EIA/IEA 库存与船流，以及下一组通胀和就业数据。
AI 持仓按经营兑现和融资依赖分层
MRVL、COHR 与 GOOG 保持现仓，MRVL 不追 8 月 19 日的急涨；MRVL 237.27 美元的常规收盘刚好位于 MA60 约 237.02 美元上方，价格确认仍很薄。COHR 的数据中心增长保留经营支持，但 287.47 美元收盘仍低于 MA30 约 304.80 美元。两者的新增预算都等到收入、毛利率、订单转收入和现金转换在财报中同时得到验证。
NBIS 的融资规模直接改变稀释与资本成本边界，成为今天最高优先级的持仓降险动作。已隐藏若最终条款显著降低稀释、资金使用转为可验证收入，可停止后续降低风险；若融资依赖扩大、现金转换继续落后，当前小仓也失去保留理由。APLD、GFS 与 PSI 暂停摊低成本，PSI 在 NVDA/MRVL 财报前冻结新增；公司级经营事实没有恶化时，不用 SMH 的弱势代替个股结论。
8 月 26 日 NVDA 和 8 月 27 日 MRVL 的实际结果是下一次统一复查点。需求、毛利率和现金转换同时超出预期，且 SMH 或 SOXX 恢复 20 日相对强度，才重新增加 AI 风险；任何一项明显落空都先压缩融资依赖标的和杠杆工具，不用盈利仓补偿弱证据仓。
医疗与能源进入新增研究预算，暂不转成新仓位
XLV 继续保持，医疗和能源各获得一条新增研究线。XLV 与 XBI 的价格、成交和临床/监管事件相互验证，RARE、REPL 进入公司级事件尽调；当前不买入，先补标签、患者池、商业化节奏、现金跑道、确认性试验和估值。确认性试验延期或失败、标签收窄，或 XLV/XBI 同时失去 20 日相对强度时取消候选。
XLE、XOP 的多窗口强势叠加 91 美元以上布伦特和 IEA 供需缺口，能源继续列为 A 级研究方向。当前仍缺公司级实现价、产量、成本、套保和资本回报，因此不把板块强势直接转成个股仓位。制裁执行与船流继续收紧、生产商自由现金流能够覆盖资本成本时再选公司；供需缺口收窄且 XLE/XOP 同时失去 5 日、20 日相对优势时结束该研究线。RSP 与 IWD 的扩散修正了昨日“广度未形成”的判断，但 IWM 20 日相对收益仍略负，暂不增配小盘或等权工具。
Crypto 反弹只取消部分价格警报，不追加杠杆
BTC 与 ETH 期货维持现有名义，冻结新增；SOL Earn 维持，不追涨。现有未实现亏损、单日反弹和正 Funding 都不构成单独减仓理由，当前保证金事实也没有显示实质恶化。反弹的含义限于价格压力缓解，无法替代底层投资逻辑、清算距离、交易场所和退出路径检查。
已隐藏不再向单一 vault 增加资金，先验证小额赎回的深度、费用和到账时间；这项验证完成前，不把链上 USDC 全额当作可即时补充 IBKR 或 Binance 保证金的现金。若可用保证金比例、清算距离、场所可用性或赎回路径实质恶化，再重算期货与收益仓的减险顺序；若这些事实保持稳定且当日 ETF 流量、跨场所价格与基差继续确认，仍只取消警报，不自动恢复杠杆。
组合事实概览
展开市场热力、期权压力和 Crypto 盘口
股票与 ETF 板块热力
云计算及平台
芯片设计与制造
MRVL+11.73%
GFS-1.12%
数据中心及算力基础设施
NBIS-7.41%
VRT-3.21%
APLD+0.67%
光通信及互连
COHR-4.52%
关键矿物
USAR-1.62%
数字资产基础设施
CRCL+12.71%
航天与国防主题
SPCX-2.75%
半导体与存储 ETF
DRAM+4.16%
KMEM+4.04%
PSI-3.60%
SOXL-2.24%
其他股票
XLV+3.49%
PLTR+1.95%
期权压力
SPY3.44
QQQ1.12
NVDA0.43
MSFT0.42
NBIS0.89
MRVL0.39
PLTR0.78
SOXX1.39
快照对比基准：2026-08-19。本面板只展示已落盘事实，不生成操作判断。
重要文章与快讯
重要文章
| 重要性 | 中文标题 | 发布日期 | 来源 | 相关标的 | 评级理由 |
|---|---|---|---|---|---|
| 5/5 高 | 英伟达财测临近，预期差收窄 | 2026-08-20 | Motley Fool | NVDA | 业绩披露临近，直接涉及NVDA，且公司指引、分析师预期、毛利率和中国收入假设具备较高事实密度。 |
| 5/5 高 | 光互联需求推升相干科技指引 | 2026-08-19 | Motley Fool | COHR | 直接覆盖COHR，财务结果、业绩指引、产能约束和订单可见度信息完整，能影响人工智能光互联板块阅读优先级。 |
| 5/5 高 | 长债回购缓解收益率压力 | 2026-08-19 | Stocktwits | BTC-USD, MRVL, NVDA, SPY, ^DJI, ^GSPC, ^NDX, ^RUT | 覆盖财政部流动性操作、长端收益率和联储政策信号，并关联NVDA、MRVL等日报标的，具有较强的宏观传导价值。 |
| 5/5 高 | AI云扩张融资引发股价下挫 | 2026-08-19 | GuruFocus.com | NBIS | 直接覆盖NBIS，45亿美元融资与即时股价反应具有较强时效性，且换股结构影响潜在稀释；最终条款仍待正式文件。 |
| 5/5 高 | 个体化黑色素瘤疗法通过三期 | 2026-08-19 | 24/7 Wall St. | BNTX, MRK, MRNA, NVDA, PFE, XLV | 三期主要终点直接关联MRNA、MRK及医疗保健板块，样本量和风险下降数据较具信息量；总生存期与监管节点仍是关键验证环节。 |
| 4/5 中高 | 谷歌扩大马威尔AI芯片合作 | 2026-08-19 | Insider Monkey | AVGO, GOOG, MRVL | 合作直接涉及MRVL且条款金额和收入里程碑具有增量价值，但文章为二次分析，正式合同和实际收入仍待验证。 |
| 4/5 高 | FDA加速批准TUDRIQEV黑色素瘤疗法 | 未提供发布时间 | Replimune Group Inc. | - | FDA加速批准为Replimune带来明确的监管与商业化节点，且文章提供了缓解率、持续时间和安全性等关键临床数据。消息发布已有约两周，批准仍依赖验证性三期试验，时效性和证据完备度低于即时监管公告。 |
| 未评级 | Oil Market Report - August 2026 | 2026-08-12 | International Energy Agency | BZ, CL | 本地未取得可读全文：HTTP 403。可使用上方“打开原文”核查。 |
| 未评级 | Marvell IR：Q2 FY2027财报电话会与2026 Investor Day | 2026-08-03 | Marvell Technology Investor Relations | MRVL | 发布时间早于日报 5 天摘要窗口。 |
| 未评级 | Binance USDS-M Futures persisted market snapshot | 未提供发布时间 | Binance | BTC, BTCUSDT, ETH, ETHUSDT, SOL, SOLUSDT | 这是 Binance BTCUSDT 行情原始快照，不是文章，且没有出版时间、事件背景或研究叙事。 |
英伟达财测临近，预期差收窄
重要性5/5 高
业绩披露临近，直接涉及NVDA，且公司指引、分析师预期、毛利率和中国收入假设具备较高事实密度。
中文摘要
核心结论
英伟达（NVDA）即将公布2027财年第二季度业绩，公司收入指引中值910亿美元与42位分析师平均预期约919亿美元仅相差约1%。文章判断，市场关注点将从收入是否超过预期转向约75%的毛利率、连续超预期能否延续，以及人工智能数据中心业务增速是否继续放缓。
重要性评级
评级：5/5（高）。文章发布时间接近英伟达业绩日，直接涉及NVDA，包含公司指引、分析师预期、历史业绩和估值等高密度事实；部分关于再次超预期的判断仍属作者推测。
关键事实
- 文章发布于美东时间 08/19 20:57（UTC+8 08/20 08:57）；英伟达计划在 08/26（未给出具体时刻）公布截至 07/26 的2027财年第二季度业绩。
- 公司5月给出的收入指引为910亿美元，上下浮动2%，对应区间约892亿至928亿美元；分析师平均预期约919亿美元，调整后每股收益约2.08美元。
- 上年同期收入为467亿美元，指引中值意味着收入接近同比翻倍；公司当前指引未计入中国数据中心算力收入。
- 上一季度收入为816亿美元，超过公司指引上限约20亿美元；数据中心收入752亿美元，同比增长92%。
- 过去四个季度调整后每股收益均超过分析师预期约3%至6%；近一个月分析师有5次上调预期、没有下调。
- 公司预计美国通用会计准则毛利率为74.9%，调整后毛利率为75%，两者上下浮动50个基点。
- 指引中值隐含环比收入增量约90亿美元，低于上一季度约135亿美元的环比增量，环比增速由20%降至约11%。
作者观点与证据
作者认为，910亿美元与919亿美元之间的差距过小，无法单独定义本次业绩风险；真正需要观察的是毛利率能否维持约75%，以及英伟达连续超预期的记录是否中断。判断依据包括上一季度超过指引上限、过去四季每股收益持续超预期和预期上修记录。重复上季度表现并无保证，估值与未来增长预期也来自作者对市场定价的分析。
与相关标的的关系
NVDA是文章直接覆盖的标的。收入和数据中心增长关系到人工智能基础设施需求的持续性；中国收入未计入指引，使任何获批销售成为额外变量。毛利率、1.6T等新产品放量和后续收入增速，可能影响市场对其高估值的解释。
时效性与限制
文章发布于美东时间 08/19 20:57（UTC+8 08/20 08:57），距离 08/26 业绩披露较近。文中估值、分析师预期和“可能再次超预期”均会随业绩定价更新，且中国数据中心收入、毛利率和实际每股收益尚未公布。
后续跟踪
- 2027财年第二季度实际收入与调整后每股收益。
- 毛利率是否接近约75%的指引。
- 数据中心收入同比增速与环比增速。
- 中国数据中心算力收入是否重新纳入后续展望。
英文原文
Nvidia Guided to $91 Billion. Wall Street Penciled In $92 Billion.
Nvidia Guided to $91 Billion. Wall Street Penciled In $92 Billion.
Daniel Sparks, The Motley Fool
Thu, August 20, 2026 at 9:57 AM GMT+9 5 min read
- NVDA
-0.99%
Nvidia (NASDAQ:NVDA) reports results for its fiscal 2027 second quarter (the period ended July 26) next Wednesday, Aug. 26. The company's own guidance, issued back in May, calls for revenue of $91.0 billion, plus or minus 2%.
Wall Street's average estimate sits near $91.9 billion, based on the 42 analyst estimates compiled by Yahoo! Finance, with adjusted earnings pegged near $2.08 per share. That's a gap of about $1 billion on a $91 billion base.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
And I think the small size of that gap is the most interesting number in the whole setup.
Image source: Nvidia.
A $1 billion gap
Nvidia's plus-or-minus 2% puts the guide's ceiling near $92.8 billion and its floor near $89.2 billion.
Wall Street's $91.9 billion lands inside that range, about 1% above the midpoint. Analysts, in effect, are projecting a beat so modest that Nvidia's own outlook already contains it. For a stock that has spent three years defined by blowout quarters, that's an unusually quiet setup.
Either number still means staggering growth, to be clear.
The year-ago quarter brought in $46.7 billion, so the guide's midpoint implies revenue close to doubling year over year. The comparison is fair, too: China data center compute revenue was essentially absent from that year-ago quarter, just as the current outlook assumes.
Nvidia keeps clearing its own bar
Recent history suggests the quiet setup is too quiet.
In May, Nvidia reported $81.6 billion of fiscal first-quarter revenue -- about $2 billion above the top of the $78.0 billion, plus-or-minus-2%, range it had guided to three months earlier. Growth ran 85% year over year and 20% sequentially, with data center revenue climbing 92% to $75.2 billion.
But the pattern holds on the bottom line, too. Nvidia's adjusted earnings per share have topped analysts' estimates by 3% to 6% in each of the past four quarters, and analysts have been nudging this quarter's numbers higher into the report -- five upward revisions over the past month, and none down, per Yahoo! Finance.
A repeat of last quarter's outperformance would put revenue near $95 billion, well above both numbers in the headline. Of course, nothing guarantees a repeat.
Zero from China, and a 75% margin
What Nvidia builds into the guide matters more than the headline figure.
Story Continues
The company said it is not assuming any data center compute revenue from China in its outlook -- a stance now in its second year, since the U.S. began requiring a license for the H20 chips Nvidia sold into China in April 2025. Any licensed China revenue that does arrive lands on top of the guide, not inside it.
Gross margin guidance sits at 74.9% on a GAAP basis and 75% non-GAAP (adjusted), each plus or minus 50 basis points, essentially flat with the first quarter.
That number could matter more than revenue. A company doubling its sales while holding a 75% gross margin is making an aggressive statement about pricing power, and a slip there could be a bigger warning than a small revenue miss.
The guide also embeds a slowdown in sequential dollars. The midpoint asks for about $9 billion of new revenue versus the first quarter, which had itself added about $13.5 billion versus the one before it. In growth terms, that's a step down to about 11% sequentially from 20%. Whether that's caution or an actual step-down in the pace of the artificial intelligence build-out is what this report should settle.
So the stakes are narrower than the headline numbers suggest.
Shares of the world's most valuable company ($5.3 trillion, for now) sit near $220 as of this writing, about 7% shy of the 52-week high of $236.54. That price is about 34 times earnings (the company earned $6.53 per share over the past 12 months). Swap in the next 12 months' projected earnings, and the figure drops to about 22.
The distance between those two multiples is the growth analysts expect from here. And the market has already paid for it.
That valuation, I'd argue, describes a market that believes the guide but expects little beyond it. Nvidia's recent record says the bar is beatable. It cleared the top of its guided range last quarter and has topped analysts' per-share estimates four quarters running.
So the risk worth watching isn't the $1 billion between Nvidia's number and Wall Street's. It's the margin line, and the first quarter in which the usual outperformance doesn't show up.
Should you buy stock in Nvidia right now?
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $419,408 ! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,348,694 !
Now, it's worth noting Stock Advisor's total average return is 966% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 19, 2026.
Daniel Sparks and his clients do not have positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy .
Nvidia Guided to $91 Billion. Wall Street Penciled In $92 Billion. was originally published by The Motley Fool
光互联需求推升相干科技指引
重要性5/5 高
直接覆盖COHR，财务结果、业绩指引、产能约束和订单可见度信息完整，能影响人工智能光互联板块阅读优先级。
中文摘要
核心结论
相干科技（COHR）管理层在2026财年第四季度电话会议中称，人工智能数据中心和通信需求推动收入、利润率及订单可见度同步改善，并预计2027财年末单季收入超过30亿美元。增长依赖800G和1.6T光模块、6英寸磷化铟扩产、光电路交换及共封装光学等项目，管理层目标与实际量产、客户订单和毛利率兑现之间仍有较大执行环节。
重要性评级
评级：5/5（高）。文章直接覆盖COHR，包含完整财务结果、下一季度指引、产能约束、订单期限和多个新产品时间表；电话会议日期早于文章发布时间，前瞻性表述占比较高。
关键事实
- 电话会议发生于美东时间 08/12 16:30（UTC+8 08/13 04:30），文章发布于美东时间 08/19 19:31（UTC+8 08/20 07:31）。
- 公司称2026财年收入为71.2亿美元，同比增长23%；按剔除已出售业务的备考口径增长28%，非美国通用会计准则每股收益为5.61美元，同比增长59%。
- 第四季度收入为20.5亿美元，同比增34%；备考收入环比增14%、同比增42%，数据中心与通信业务占第四季度总收入约79%。
- 第四季度非美国通用会计准则毛利率为40.2%，环比提高66个基点；全年毛利率为39.4%，同比提高152个基点，全年经营利润率升至20.5%。
- 公司预计2027财年第一季度收入22亿至24亿美元、非美国通用会计准则毛利率39.5%至41.5%、每股收益1.85至2.05美元。
- 管理层预计在当前季度末将内部磷化铟产能同比翻倍，并在2027年末再次实现超过翻倍；6月季度磷化铟激光器产量同比增长约80%。
- 数据中心收入在第四季度同比增长66%；800G继续增长，1.6T在2026年下半年至2027年加速放量，共封装光学预计从12月所在季度开始贡献收入。
- 客户采购订单已覆盖至2027年末并开始延伸至2028年，长期供货协议（LTA）部分延伸至本十年末；光电路交换市场机会估计超过40亿美元，集成光学增量市场机会估计超过150亿美元。
作者观点与证据
文章是Motley Fool整理的公司电话会议记录，主要呈现首席执行官James Robert Anderson和首席财务官Sherri R. Luther的观点。管理层把订单增长、磷化铟产能、6英寸成本结构、客户长期协议和新产品放量作为收入与毛利率扩张依据，并称数据中心投资回收期约18个月。财务数字和指引来自公司披露，市场机会、订单可见度及未来增长属于管理层陈述，尚未由后续季度结果独立验证。
与相关标的的关系
COHR是文章直接标的。其业务与人工智能数据中心光互联需求相关，收入增长路径包括800G和1.6T光模块、光电路交换、共封装光学、近封装光学及热管理。磷化铟扩产既是供给瓶颈的解决方案，也关系到毛利率改善；共封装光学在2027财年第二季度启动收入、规模扩展和客户认证是重要节点。
时效性与限制
文章发布于美东时间 08/19 19:31（UTC+8 08/20 07:31），但电话会议内容截至 08/12。文中包含大量管理层预测和市场规模估算，且原始转录存在个别数字及语句识别不完整的情况；税率指引等细节应以公司正式业绩材料为准。
后续跟踪
- 2027财年第一季度收入、毛利率和每股收益是否落在指引区间。
- 6英寸磷化铟产能翻倍和1.6T光模块放量的实际进度。
- 共封装光学在12月所在季度的收入确认及客户认证。
- 订单覆盖、长期供货协议执行和数据中心业务毛利率变化。
英文原文
Coherent (COHR) Q4 2026 Earnings Call Transcript
Coherent (COHR) Q4 2026 Earnings Call Transcript
Motley Fool Transcribing, The Motley Fool
Thu, August 20, 2026 at 8:31 AM GMT+9 7 min read
- COHR
-6.19%
Image source: The Motley Fool.
DATE
Wednesday, Aug. 12, 2026 at 4:30 p.m. ET
CALL PARTICIPANTS
- Senior Vice President of Investor Relations - Paul Jonas Silverstein
- Chief Executive Officer - James Robert Anderson
- Chief Financial Officer - Sherri R. Luther
Full Conference Call Transcript
Operator: Greetings, and welcome to the Coherent Fourth Quarter and Fiscal Year 26 Earnings Call. It is now my pleasure to introduce your host, Mr. Paul Jonas Silverstein, Senior Vice President of Investor Relations for Coherent. Please go ahead.
Paul Jonas Silverstein: Thank you, operator, and good afternoon, everyone. With me today are Jim Anderson, Coherent's CEO and Sherri R. Luther, Coherent's CFO. During today's call, we will provide a financial and business review of the fourth quarter of fiscal 26, and the business outlook for the first quarter of fiscal 27. Our earnings press release can be found in the Investor Relations section of our company website at coherent.com. I would like to remind everyone that during our conference call, you may make projections or other forward looking statements regarding future events or the future financial performance of the company. These are subject to a number of significant risks and uncertainties and our actual results may differ materially.
For a discussion of factors that could affect our future financial results and business, please refer to the disclosure in today's earnings release. Our most recent Forms 10 ks and 10 Q and the reports that we may file on Form 8 ks with the Securities and Exchange Commission. All our statements are made as of today, August 12, 2026, based on information currently available to us. Except as required by law, we assume no obligation to update any such statements. During this call, we will discuss non GAAP financial measures.
You can find a reconciliation of these non GAAP financial measures to GAAP financial measures in our earnings release and investor presentation that can be found on the Investor Relations section of our website at coherent.com. Let me now turn the call over to our CEO, Jim Anderson.
James Robert Anderson: Thank you, Paul, and thank you everyone for joining today's call. Fiscal 26 was an outstanding year for Coherent. On a pro forma basis, revenue increased 28% to a record $7 billion Our revenue growth combined with gross margin expansion and continued operating leverage drove non GAAP EPS growth of approximately 59% more than twice the rate of revenue growth. We also finished the year with significant momentum. In Q4, our pro forma revenue growth rate accelerated significantly with revenue increasing 14% sequentially, and 42% year over year, while non GAAP EPS increased 74% year over year. Our accelerated growth rate reflects the exceptional demand environment and our continued rapid expansion of production capacity.
Story Continues
While we are very pleased with our fiscal 26 performance, we are even more excited about the year ahead. We expect our growth to accelerate significantly in fiscal 2027. Having achieved our first $2 billion revenue quarter, we now expect to achieve our first quarter with over $3 billion of revenue by the end of fiscal 27. Coherent is a global leader in photonic technology. Our broad photonic technology platform is foundational to the performance and scalability of AI data centers. AI runs on compute, but it scales on optical connectivity.
Coherent is at the center of an extraordinary expansion in optical networking infrastructure, driven by the rapid growth of AI, the transition from copper to optical connectivity, and the increasing need for bandwidth and energy efficiency across increasingly large and complex data center architectures. Our competence in fiscal 27 is based on 3 factors. First, customer demand continues to grow. As demonstrated by another quarter of record bookings. Second, our supply of critical components is increasing, including the planned doubling of our internal Indium Phosphide year over year by the end of the current quarter. Third, multiple new revenue streams are expected to ramp over the coming quarters.
Including Optical Circuit Switching, co-packaged optics, multi-rail systems, and advanced materials for data center thermal and power management. Along with strong revenue growth, we expect continued gross margin expansion and operating leverage enabling us to grow EPS significantly faster than revenue. We expect fiscal 27 to be another outstanding year for Coherent. Our data center and communications segment continues to be the primary driver of our growth and accounted for 79% of total company revenue in Q4. Segment revenue increased 40% for full year fiscal 26. In Q4, our segment revenue growth rate accelerated significantly revenue increasing 19% sequentially and 59% year over year.
Demand continues to strengthen, driving another quarter of record bookings and extending our visibility further into the future. Our order coverage through calendar 27 is exceptional. Customer orders now extend into calendar 28. Customer LTAs extend through the end of the decade. We continue to see no signs of attenuation in customer demand. Our broad photonic technology portfolio manufacturing scale, and significant US production footprint are increasingly differentiating Coherent with customers and translating into deeper longer term partnerships and revenue opportunities. In our data center business, revenue increased 41% for full year fiscal 26. In Q4, our data center revenue growth rate accelerated significantly, revenue increasing 24% sequentially and 66% year over year.
This marked our third consecutive quarter of double digit sequential growth and we expect strong sequential growth again in the current quarter. Demand in our data center business remains exceptionally strong and broad based across multiple customers and product categories. Within transceivers, we expect growth to be driven by both 800G and 1.6T. We expect 800G revenue to continue growing year over year in calendar 2026, while 1.60 transceivers ramp rapidly through the balance of calendar 2026 and into calendar 2027, as adoption broadens across customers. Beyond transceivers, OCS revenue increased sequentially in Q4 we expect continued growth over the coming quarters as we expand production capacity.
We also expect CPO to begin contributing to revenue growth in fiscal Q2, consistent with our planned production ramp. Our 6-inch Indium Phosphide capacity expansion is a key driver of revenue growth and margin expansion. We remain on track to double our internal Indium Phosphide output capacity year over year by the end of the current quarter, 1 quarter ahead of our original plan. This ramp contributed meaningfully to our data center revenue growth in Q4 and we expect it to remain an important growth driver in Q1. Looking further ahead, we remain on track to more than double our internal Indium Phosphide output capacity again by the end of calendar 27.
We have secured the substrates and other critical inputs required to support this ramp. Given the strength of customer demand, we are planning additional capacity beyond 2027. Our capacity expansion is being driven by the transition to 6-inch Indium Phosphide production. Our 6-inch lines in Texas and Sweden are producing EMLs CW lasers, and photodiodes with yields that continue to exceed our 3-inch lines. We remain on track to begin 6-inch production in Zurich during the first half of calendar 2027, further extending what we believe is a meaningful manufacturing advantage. Our Texas facility has also begun ramping our ultra high power CW laser for CPO solutions. Including those covered by our NVIDIA partnership.
With revenue expected to begin ramping in Q2. Turning to OCS, revenue increased in Q4 as we continue to ramp production. Given strong customer demand across our 320x320 platform, and other system sizes, we expect OCS revenue to grow significantly through fiscal 27. We continue to estimate that OCS represents more than $4 billion of addressable market opportunity across data center interconnect, scale-out and scale-up networks. As we expand production across 2 manufacturing locations, we expect OCS to become an increasingly meaningful contributor to revenue growth and margin expansion. CPO, NPO, and other forms of integrated optics represent a tremendous growth opportunity for Coherent.
These technologies enable the transition from copper to optical connectivity represent more than $15 billion of incremental addressable market opportunity the coming years. At the ECOC industry event in September, we plan to unveil coherent PhotonLink, our new platform for integrated optics. PhotonLink spans the complete optical signal chain from light generation and beam shaping through transmission, detection, and conversion back to an electric signal for the XPU or switch ASIC. Platform supports CPO, NPO, and other forms of optical integration. PhotonLink leverages the breadth of coherent photonic technology portfolio and manufacturing capabilities to enable next generation data center architectures that use optical links to achieve new levels of bandwidth, performance, and energy efficiency.
We have deep engagements with multiple customers across both TPO and NPO applications. We believe offer comparable content opportunities for Coherent. We expect initial revenue from PhotonLink related products to begin in our December quarter We will share additional details about PhotonLink at our launch event on September 21. Turning to our communications business, customer demand remained exceptionally strong in Q4. Communications revenue increased approximately 54% for full year fiscal 26. Q4 revenue increased 11% sequentially and 56% year over year, driven by continued strength across data center interconnect, scale-out, traditional telecom applications. We expect another quarter of strong sequential growth in Q1.
Demand remains broad based across our portfolio with particular strength in DCI solutions, including ZR and ZR plus transceivers dwells pump lasers and complex high end optical subsystems. Multi rail is an important new growth opportunity in our communications business, addressing scale-out AI networking as workloads increasingly span multiple data centers require greater bandwidth between locations. We estimate a more than $2 billion addressable market by calendar 2030, continue to expect initial revenue to ramp in the first half of calendar 27. Preparation for the expected revenue ramp we recently delivered samples to multiple customers.
We believe Coherent is well positioned with a broad technology portfolio differentiated density and power efficiency, strong customer engagement, We expect multi-rail to become a meaningful contributor to revenue growth and margin expansion over time. Turning to our Industrial segment, revenue was roughly flat on a pro forma basis in both fiscal 26 and Q4. In Q4, semiconductor capital equipment and display capital equipment both grew sequentially and year over year offset by continued weakness across broader industrial markets. We expect growth to resume over the coming quarters, led by semiconductor capital equipment where bookings continue to strengthen.
Over the longer term, we see meaningful growth opportunities across several emerging applications, 1 example is data center XPU cooling where our proprietary thermodynamic material can improve thermal performance and enable higher XPU performance. Which can translate into greater AI token generation per XPU. We are engaged with multiple strategic customers and have delivered samples of our thermodynamic cooling solutions. We expect revenue to begin ramping in the second half of calendar 27, representing a meaningful expansion of our long term market opportunity. We also see longer term opportunities in fusion energy, quantum technologies, and micro LED display capital equipment.
Overall, we believe industrial is positioned to return to growth and become an increasingly important source of revenue diversification over time. In summary, we enter fiscal 27 with exceptional customer demand, record visibility, expanding production capacity, and multiple new growth platforms beginning to ramp. We believe Coherent is uniquely positioned to capitalize on the multiyear expansion of AI data center infrastructure supported by the breadth of our photonic technology portfolio, our manufacturing scale, and our significant US production footprint. I want to thank the entire Coherent team for their outstanding execution and innovation throughout fiscal 26. I will now turn the call over to Sherri.
Sherri R. Luther: Thank you, Jim. Fiscal 26 was an exceptional year for Coherent. We delivered record revenue of $7.12 billion, expanded gross margin by over 150 basis points, increased operating margin by nearly 300 basis points, and grew non GAAP earnings per share by 59% significantly faster than revenue growth. We also strengthened our balance sheet, reducing debt leverage to 0.7 times from 2 times at the end of FY 25 while continuing to invest in capacity as well as our product road map to support the growing AI data center and communications demand. Let me now provide a summary of our results.
Fourth quarter revenue was a record $2.05 billion, up 13% sequentially and 34% year over year, driven by growth in AI data center and communications demand. On a pro forma basis, revenue increased 14% sequentially and 42% year over year. Excluding revenue from the aerospace and defense business and the Munich Germany product division, which were sold in Q1 and Q3, respectively. Full year 2026 revenue was $7.12 billion up 23% from 2025 and up 28% on a pro forma basis. AI data center and communication strength was the key driver of our full year 2026 revenue growth. Fiscal 26 was the first year in Coherent's history to exceed $7 billion in revenue.
Our Q4 non GAAP gross margin was 40.2% a 66 basis point improvement compared to the prior quarter and a 215 basis point improvement compared to the year ago quarter. Our full year 2026 non GAAP gross margin was 39.4% up 152 basis points from 2025. Gross margin performance continued to improve both sequentially and year over year as a result of the initiatives we have been executing throughout fiscal 26. We saw benefits from our gross margin expansion strategy primarily within data center and communications segment. These improvements were driven by lower product input costs improved manufacturing yields and efficiencies, including continued progress on our 6-inch Indium Phosphide platform, as well as benefits from our pricing optimization efforts.
We expect gross margin to continue to improve over the coming quarters as pricing optimization and cost structure improvements such as increasing capacity from our 6-inch Indium Phosphide platform continue to take effect. Fourth quarter non GAAP operating expense was $377 million compared to $348 million in the prior quarter and $307 million in the year ago quarter. Non GAAP operating expense as a percentage of revenue decreased to 18.4% in Q4 from 19.3% in Q3 and 20.1% in the year ago quarter. As we continue to focus on driving better leverage and operating efficiencies.
Full year 2026 non GAAP operating expense increased to $1.35 billion from $1.17 billion in FY 2025 primarily driven by increased investments in our product portfolio. As a percent of revenue, operating expenses decreased 19% in 2026 from 20.1% in 2025. R&D expense as a percentage of revenue increased 10.2% in Q4 from 9.9% in the prior quarter and 9.8% in the year ago quarter. For the full year, R&D expense as a percentage of revenue increased 9.7% compared to 9.5% in FY 2025. The sequential and year over year increases were driven primarily by investments within the data center and communications segment product portfolio. R&D investments remain focused in areas where we see the strongest long term growth opportunities.
Including transceivers, CPO, OCS systems, and thermal management solutions We continue to prioritize investments that address customer demand while generating attractive returns and supporting future growth. SG&A expense declined to 8.2% of revenue in Q4 compared to 9.4% in the prior quarter and 10.3% in the year ago quarter. For the full year, SG&A expense decreased 9.2% of revenue from 10.5% in FY 2025 reflecting continued progress and driving efficiencies and generating greater operating leverage. During fiscal 26, we made significant progress simplifying our operating model and driving greater operational efficiency. The expansion of our regional shared services structure has reduced costs improved process consistency, and improved leverage across our global operations.
The benefits realized during the year exceeded our original expectations, and we expect these benefits to continue to increase throughout fiscal year 27. Our fourth quarter non GAAP operating margin increased to 21.8% compared to 20.3% in the prior quarter and 18% in the year ago quarter. Our full year 2026 non GAAP operating margin increased 20.5% from 17.8% in FY 2025. The increases for both Q4 and FY 2026 were driven by strong revenue growth continued gross margin expansion, and improved operating leverage. Fourth quarter non GAAP earnings per diluted share was $1.74 up 23% from the third quarter and up 74% from the year ago quarter.
FY 2026 non GAAP earnings per share was $5.61 up 59% from FY 2025. Earnings growth continued to outpace revenue growth in both the quarter and the full year, driven by strong revenue performance gross margin expansion, and improved operating leverage. Our FY 2026 year end cash balance of 2.59 billion compares to $3.05 billion at the end of the prior quarter. And $1.63 billion at the end of FY 2025. Consistent with our capital allocation priorities we continued investing in opportunities that we believe will drive long term growth and profitability. These investments were primarily focused on expanding data center and communications capacity and advancing our product development road maps.
During FY 2026, we made 513 million in debt payments exiting the year with a debt leverage ratio of 0.7 times compared to 2x at the end of FY 2025. Our capital expenditures increased $556 million up from $290 million last quarter and 131 million in the year ago period. This acceleration directly supports future growth across our data center and communications business These strategic investments are expected to yield excellent financial returns For example, the investments we are making in the data center business have a roughly 18 month payback period. Our conviction in these high return investments backed by excellent visibility from our customers with a robust pipeline of strong purchase orders and long term agreements.
This CapEx is primarily directed towards advanced tooling and state of the art manufacturing equipment that accelerates our volume manufacturing capabilities and optimizes production yields. Furthermore, as a vertically integrated manufacturer, this capacity offers significant fungibility as our infrastructure can be dynamically repurposed support multiple product lines. Given the exceptional demand profile and clear ROI visibility, we expect capital expenditures to increase sequentially again in Q1. These results reflect strong customer demand, disciplined operational execution, continued progress on our gross margin expansion initiatives, and investments in the products and technologies that we believe will drive future growth. I will now turn to our guidance for the first quarter of fiscal 27.
We expect revenue to be between 2.2 billion and 2.4 billion We expect non GAAP gross margin to be between 39.541.5% We expect total operating expenses of between $400 million and $420 million on a non GAAP basis We expect the tax rate for the quarter to be between 1.82 thousand% on a non GAAP basis. We expect EPS of between a $1.85 and $2.05 on a non GAAP basis. We are entering fiscal 27 with strong momentum. Supported by record backlog, excellent visibility into customer demand, and a significantly stronger financial position. We remain focused on expanding capacity, improving profitability, and allocating capital in a disciplined manner as we support future growth and drive long term shareholder value.
That concludes my formal comments. Operator, please open the call for Q&A.
Operator: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. 1 moment, while we poll for questions. Our first question is from Samik Chatterjee with JPMorgan. Please proceed with your question.
Joe: Hi, good afternoon and thanks for taking the questions. Maybe for my first, it sounds like you continue to make good progress on the 6-inch ramp and even hinting at further expansion beyond 2027. Can you provide us an update on the ramp and specifically how we should be thinking about how it translates into revenue and gross margins? And then I have a follow-up. Thank you.
James Robert Anderson: Yes. Thanks, Samik, for the question. Yes, I would say, I am quite pleased with the progress on our 6-inch Indium Phosphide ramp. I think the team is doing just an outstanding job of ramping that production. As I mentioned in the prepared remarks, we are on track to double the output capacity of Indium Phosphide production. This quarter. that is 1 quarter earlier. Than our original plan. And then by the end of next calendar year, we expect to more than double it again. So we are on a pretty fast pace of expansion and executing well to that. And actually a little ahead of our plan.
So really pleased with that And maybe a helpful data point just to kind of measure our progress along the way is if I look at our June quarter and I look at, well, how many lasers, Indium Phosphide lasers did we produce in our June quarter, on a year over year basis, we produced about 80 about 80% more Indium Phosphide lasers in our June quarter than we did the prior year. So 80% year over year growth. And those are the lasers that go specifically into our 800 gig transceivers and our 1.6T transceivers.
And so that 80% growth year over year, I see that as a really good measure of progress towards, you know, continuing to expand our Indium Phosphide capacity. And then I think you asked how does that relate to revenue You know, that 80% growth in lasers in the June quarter, we use those basically go into transceiver shipments in the current quarter. And so we would expect our data center growth, for instance, this quarter on a year over year basis to exceed 80%. Right? We certainly got the lasers this quarter to make that happen, And so that is kind of how you can think about how it impacts the data center transceiver revenue growth.
And, you know, I just a couple other comments on the progress. 1 of the things I continue to be pleased by is our yields. Our yields continue to be better than our 3-inch production. So yields of 6-inch better than 3-inch, and that is across all 3 devices that we have in production. That CW, EML, and photodiodes. And so all 3 showing better yields than 3-inch. And you know, another milestone that I mentioned in prepared remarks, we have now you know, we are starting production and ramping production of our ultra high power CW lasers that go into CPO applications. We will see revenue from those.
We expect in our December quarter, it is our Texas and Sweden plants that are ramping right now. So we are ramping in 2 locations. 6 inch, and we will bring a third 6-inch location online We expect in the first half of calendar 27. So yeah, I would say the progress, quite pleased with it. So And then I it sounded like, Samik, you had a follow-up question?
Joe: Yes. And the second 1 and very useful color there. Thanks, Jim. The second 1 is and maybe you started touching on this, but the CPO revenue starting in December quarter, Just curious, can you shed any light or additional color around the opportunity, both near and long term, just particularly given the recent noise surrounding it from the market perspective around concerns around delays and maybe the forward pull-in of NPO. Just curious in terms of if any other color you can share there just given kind of all that noise surrounding it. Thank you.
James Robert Anderson: Yeah. Sure. Thanks, Samik. Yeah. First of all, we have seen absolutely no push out of CPO demand. In fact, it is been the opposite. We have seen demand increase and demand request from customers demand getting pulled in. And so we have only seen the opposite. And then that is on CPO specifically. And then the other thing that we have seen, especially over the last 3 to 6 months, is a significant ramp up in the engagement with customers on not just CPO, but now NPO.
So I would say we have, you know, multiple very important engagements across many customers, around either CPO or NPO And so the, yeah, the intensity is has really gone up over the last 3 to 6 months. And so we are really pleased to see that. And just as a reminder, when we talk about integrated optics, whether it is CPO or NPO or any other form of it, we have a very wide portfolio that we can bring to our customers. it is not just 1 ingredient, but a really wide range of products. it is of course, it is the laser. We have you know, we have very strong laser capabilities.
But the laser, the external laser module the optical components that go into that external laser module, like isolators, We manufacture polarization maintaining fiber. This is the type of fiber that you would use to connect the laser module to the device or the device back to the front panel We have got the we can do the full assembly of the entire fiber attach kit. We do the SiPho PICs. So we are able to bring to our customers a full range of integrated optics capability. And we see NPO or CPO to us, it is just a different form factor.
The amount of content that we would have in an NPO application versus a CPO is very comparable, very similar. And so we are just we are driving whatever the customer prefers in terms of their type of application, CPO or NPO. We are there to support them. And then the other thing that we are going to be launching in September that I mentioned is a new platform technology platform called PhotonLink. And what we were seeing with customers around CPO and NPO is customers not wanting to just buy a point individual ingredient like a laser or an isolator, but really wanting help bringing the full the full solution.
And so what PhotonLink is it is our integrated platform for basically being the 1 stop shop for integrated optics platform. And so it spans all the way from light generation to beam shaping and transport transmission to detection and conversion back to the signal. So we will talk more about it at our product launch event in September. But we think that is, you know, based on the initial customer reaction, great. You know, great solution for customers that want more of a complete solution. So we are pretty excited about that as well. Thank you. Appreciate all the details.
Operator: Our next question is from Simon Leopold with Raymond James. Please proceed with your question.
Simon Leopold: Great. Thank you very much for taking the question. The first thing I wanted to ask you about and I know this, it is not a done deal, but there is been press coverage on potential import restrictions for optical transceivers. And I think I have 2 parts to this question. The first aspect is what does it mean to Coherent specifically? And part of this would I think it applies to the CHIPS Act, creating US jobs. So could you in practice move transceiver manufacturing? Would you or could you move that to The US? And then I have got a follow-up. Thank you.
James Robert Anderson: Yeah. Thanks, Simon. So, you know, that report is speculative at this point. But, you know, certainly, we would benefit from something like that as the as the main, you know, the largest US supplier of transceivers, something like that would certainly be beneficial. Although, you know, we always want to compete for our customers' business based on our technology and based on our manufacturing. And we think we have got the broadest, deepest photonic technology in the industry and the most extensive manufacturing footprint. And 1 of the things that we are really proud about on our manufacturing is of course, we are a global manufacturer with locations all over the world, which gives us resiliency.
Of course, we are also vertically integrated. We build a number of the very important components ourselves. But, Simon, as you mentioned, we have an outside footprint in The US. We have over 20 production facilities in The US, and that I think is really a strategic advantage for us. You know, just 1 example is that Sherman, Texas facility. We are making very critical components in Sherman, Texas for not just transceivers, but for CPO and NPO applications. And there is other facilities throughout the US where we make other critical components like fiber optic cable, like growing the garnet that goes in the isolators for transceivers.
So to the extent that we need to we are already investing US manufacturing, but to the extent we need to increase that US manufacturing we would certainly be open to doing that. We have got we were founded over 50 years ago as a US manufacturing company And so we have a great footprint, and we could certainly build off of that. Thanks.
Simon Leopold: And then just the follow-up is I think it was you gave us a target for Q4 2027, June 2027 of revenue exceeding $3 billion I think that is well above current consensus. I would like to get a better sense then of what you are thinking about your gross margin. I know in the past, you have talked about a target of 42.5%. Wondering if you could update us given sort of the shifts in growth in the mix, how you are thinking about the gross margin trajectory? Thank you.
James Robert Anderson: Yeah. I will pass that 1 on to Sherri to comment on gross margin. But the, you know, the quick version is that we have made, I think, great progress over the past quarters, and we are certainly super focused on continuing to make progress moving forward. But, Sherri, do you want to add color to that?
Sherri R. Luther: Sure. Sure, Jim. Thanks, Simon. So first of I would like to say I am extremely pleased with the progress we have made in improving gross margin. We increased gross margin 66 basis points sequentially and 250 basis points year over year. In fact, in 8 out of the past 9 quarters, we have increased our gross margin. So that is not just a trend. that is showing that we are actively driving gross margin improvement. And the accumulation of improvement was over 660 basis points of improvement. So clearly, an area that we are actively driving and focused on. Now the target, that we gave at our Investor Day of greater than 42%.
And at the midpoint of our Q1 guide, which is at 40.5%, you know, that is you know, certainly, we are we are still early. We have a little bit of ways to go. I do view that we are early in our you know, in our strategy for gross margin expansion, but we are extremely focused on getting to greater than 42%. And let me tell you why I am confident. The bulk of the 6-inch Indium Phosphide product ramp is still ahead of us. that is still to come. New product ramps for 1.6T OCS system CPO multi-rail systems, thermal management solutions, all of those new products, those ramps are all still to come.
They are all ahead of us. And of course, we will continue to drive cost reductions, pricing optimization improvements, the bulk of those improvements driven to date are in these areas, and we have clear plans to drive you know, what I view as a very significant opportunity ahead. So once we get to our target of greater than 42%, we will no doubt raise the target. Thank you. Thanks, Simon. Thanks, Simon.
Operator: Our next question is from George Notter with Wolfe Research. Please proceed with your question.
George Notter: Hi, guys. Thanks very much. I guess I was just curious about where you are in terms of your transceiver mix right now. Obviously, there is an initiative to insource as much of those laser datacom chips as you can. I am just curious, like, how much of your mix is now, you know, insourced in terms of the laser datacom chip? And then also, I know there was a plan to kind of, you know, exceed your own internal needs and supply EMLs externally. I am just curious, like, what the road map looks like for, you know, selling EMLs commercially in the market. Thanks.
James Robert Anderson: Yeah. Thanks, George. I think on the last point, given the demand that we see in our data center business with transceivers, I do not see any time in the near future where we would be selling Indium Phosphide lasers externally. Our data center transceiver demand is absorbing every bit of capacity. That we have and then some. So I do not I do not see any near term ability to do that. Maybe further out, but today, we use a mix of internal internally produced and externally sourced. I still believe that over the long term, we will have some portion of our datacom transceivers that will be supported by external sources.
I think that is there is a number of strategic reasons why that is good for the transceiver business. But certainly, think as we expand our internal production, which is growing very quickly, I talked about the 80% year over year growth that we saw in laser production. In our June quarter, and that will grow from here given the ramp in Indium Phosphide, You know, I would expect over time for a greater percentage of our transceivers to be serviced with internal Indium Phosphide. Great, thank you.
George Notter: And then just as a quick follow on, I am curious about where you are on VCSELs. It seems like there is a lot of new enthusiasm around VCSELs in scale up applications. Obviously, you guys are working on a 200G VCSEL. I am just curious about where that is and how do you see that opportunity for Coherent? Thanks.
James Robert Anderson: Yeah. I think that is a great tool in our chest. Right? Is in our tool chest is the 200G VCSEL. We continue to make good progress on that. I do think that 200G VCSEL will see adoption in integrated optics applications. In you know, like, NPO type of applications. And so we are actively working with customers on VCSEL-related NPO or integrated optics application. So that is certainly an important tool, and, yeah, we think that will be deployed. Thank you.
Operator: Our next question is from Ryan Koontz with Needham and Company. Please proceed with your question.
Ryan Koontz: Great, thanks. I want to ask about your capacity constraints here. I wonder if you could look at kind of your input capacity constraints as well as your own internal production capacity constraints? And how should investors think about those and where you are investing now? But where are your sharpest pain points now to grow the business over the next 12 months?
James Robert Anderson: Yeah. Thanks, Ryan. I would not say that any-- Indium Phosphide capacity continues to be our primary constraint. that is why we are so focused on ramping that 6-inch production. That we are not constrained, for instance, if you look at transceivers, we are not constrained in the assembly and test capacity right now. We have that capacity available. We are really just constrained by the ramp of the Indium Phosphide production. And so as we as we continue to ramp that Indium Phosphide output, we expect that to continue to help drive revenue growth for our transceivers. So it is it is really as simple as that. that is the primary constraint.
Ryan Koontz: Helpful. Thank you. And maybe as you think about, the telecom side of the world and multi-rail and pump lasers and all that is involved there, You know, how do you, think about that monetization opportunity in terms of various parts or systems you might sell into that market?
James Robert Anderson: Yeah. Thanks, Ryan. In that market, we actually sell a multiple different levels, so we do sell components into that market, we sell what I would call subsystems. So these should be amplifiers, line cards, in some cases, we will sell kind of full systems. And so we sell at multiple levels, and I would say the growth there is incredibly strong. You know, in communications, the kind of scale-out DCI falls within our communications business. We saw in our June quarter 56% year over year growth in that segment.
I think that segment moving forward, we are gonna continue to see faster growth just as we have seen in the sort of data center applications and that is across, just a multiple different products, whether it is our ZR/ZR+, transceivers, whether it is some of the components like the pump lasers or the products that go into the pump lasers. And then as I mentioned in the prepared remarks, soon you know, we will start to see revenue from a multi-rail So the our technology for multi-rail systems is in the hands of customers now. We have sampled that. And we expect revenue to start to flow from multi-rail in the first half of calendar 27.
So, yeah, there is just a wide range of products there, and I would say the demand just continues to go up for anything DCI or scale-out related. Super. Thanks, Jim.
Operator: Our next question is from Blayne Curtis with Jefferies. Please proceed with your question.
Blayne Curtis: Hey, good afternoon, guys. I had 2 questions. First, maybe you could just talk about the OCS demand. I mean, you mentioned the $4 billion TAM. I think you are starting to ship in smaller volumes. Can you just talk about where you are seeing the demand, how broad that is? And, you know, I think there is expanding applications as well, like inter-rack and such. Can you just comment on that?
James Robert Anderson: Yeah. Definitely, Blayne. We are certainly seeing an expanding range of applications. So you know, originally, when we started working on OCS, we were thinking about it mostly in the in the context of scale out. But now, clearly, we think we will see adoption and scale-out and then a clear path to scale up as well. So have active customer engagements in scale up applications. And so that is really what led us to double the size of our market outlook at OFC earlier this year. So we doubled it from 2 to over 4 billion. And we may have even been conservative on that $4 billion number in terms of the addressable market over time.
I think that was for a 2020, 2030 time frame. And so, yeah, we have only seen the application widen, and the demand looks stronger than what we had thought 6 or 12 months ago. So it looks very good. And then in terms of our progress, yeah, pleased with our progress. The demand is clearly at there, and so we are really just focused on ramping manufacturing capacity as fast as we can. We saw revenue grow in our June quarter, and as I look forward over the coming quarters, we expect to continue to expand production capacity and then drive faster revenue growth as well.
So we believe it becomes a very meaningful product line over time for us. Thanks.
Blayne Curtis: And then I want to go back to NPO. If you could just talk about, is there a way to kind of think about how many projects you are working on? And then I just wanna drill down on there is a lot of questions on you said the content would be similar to CPO. But then I think there is some talk about integrated, and then you answered a question talking about VCSELs. So can you just walk through that content? Where are you seeing the demand Is it kind of even on the projects you are working on now, and it might change in the future? Can you just walk through that?
James Robert Anderson: Sure. And what I would say is with almost every customer that we work with, certainly large strategic customers, we have either a CPO or an NPO or in some cases, a CPO and NPO project ongoing. So and that is really that sort of intensity and engagement around CPO and/or NPO has really gone up over the last 3 to 6 months. And so I would say those engagements are very active. And just as a reminder, as I said earlier, we are, you know, we are not just bringing 1 ingredient like a laser to the solution. Bringing a full platform solution The laser, the interconnect, the different optical components etcetera.
So we I would say, you know, engagements across all the major customers. And then on the second part of your question on the dollars of content, yeah, we see comparable levels of content for both CPO and NPO. To us, it is just a different attach point, whether it is connecting directly near the piece of silicon or whether it is on the motherboard, NPO or the level of content that we would see, we view as very similar. And maybe that is because we are we are providing a pretty broad range of solutions in both of those types of applications. But we see the level of content similar.
And I would say all of this, I would point out, is incremental addressable market for us, but also for the optics industry in general. I mean, most of these projects are focused on scale up applications where we are gonna be converting more of those copper electrical lines to optical over the coming years. So it is it is great addressable market expansion for us, and we expect it to be a major growth area for us. Thanks, Tim.
Operator: Our next question is from Karl Ackerman with BNP Paribas. Please proceed with your question.
Karl Ackerman: Yes, thank you. I have 2, if I may. First question, Jim, you spoke about quarterly revenue exceeding $3 billion by the end of fiscal 27, which is quite robust. Could you unpack that a bit and describe how much of that is an uplift from perhaps 1.6T transceivers? You talked about OCS demand. You talked about multi rail. Perhaps how much of this is coming from any backlog or pricing as well If you just kind of bucketize those, it would be very helpful. And I have a follow-up. Yeah.
James Robert Anderson: Thanks, Karl. So first of all, you know, that is all the primary driver there is data center and communications. We expect some improvement in industrial but it is really the bulk of that is driven by data center and communications given that is 80% of our revenue. And then within that, I would say, certainly, transceivers is a big driver of that. You know, we have got 800G is still growing very robustly on a year over year basis, and then 1.6T is ramping incredibly fast. In fact, we have seen the 1.6T ramp only the pull in be stronger, demand increase, and so that ramp is even faster than what we thought say, 3 months ago.
So 800G, 1.6T transceiver is certainly a key part of that. But beyond that, OCS ramping through the course of this fiscal year. CPO now starting to really kick in, in the December our December quarter. And ramping in the following quarters. We talked about multi-rail as well And then, yeah, there are pricing improvements that we are driving, either kinda normal pricing improvements or pricing improvements are part of our LTAs, long term agreements with our customers. That are kicking in as well. So it is really a number of factors Across, you know, across data center and communications, we are I am trying to think if there is any product line where we are not supply constrained on.
The demand is robust across almost every single product. Across data center and comms and it is really just a matter of as fast, we can sell as fast as we can ramp production. And so our we have had just an extreme focus on ramping production as quickly as possible. Thank you.
Karl Ackerman: And then you also spoke about how customer orders extend into 2028 and LTAs to the end of the decade. When you discuss LTAs extending into 2028, is that volume committed in 2028 at a higher volume commitment 2027? Perhaps you could provide some guardrails with respect to the volume commitments that you are seeing today and how that is improved over the last 90 days? Thank you.
James Robert Anderson: Yes. Thanks, Karl. So first of all, on the when I am talking about the near term, we are talking about purchase orders or backlog. And so in terms of backlog and bookings, we take, like, our June quarter, we saw I would call, just an extraordinary level of bookings, record bookings, again in our June quarter, and so our backlog now extends out--you know, fiscal 27 is basically completely booked out We are booked really through the end of calendar 2027. And what we are seeing now is, you know, customers now looking into calendar 2028. Right? So those are those are purchase orders for specific products etcetera.
So that is really good because that is very high quality near term demand visibility. And then at the same time in parallel, a lot of customers putting in place long term agreements with us. Where long term agreements for supply over a multiyear period. Many of those periods extending out through the through the end of the decade. And yeah, generally, those agreements have, you know, increasing supply each year because what we are doing is we are expanding capacity to bring on or to support their demand requirements moving forward. So expanding capacity, expanding demand from them. And then they have pricing related commitments.
And then they also have sort of minimum demand guarantees from our customers or sometimes you refer to those as take or pay agreements. And so those LTAs are also really helpful. Those give us a great visibility just beyond 2028. Those give us really good visibility into the key products we need to be building and the capacity we need to be expanding through the rest of the decade.
Operator: Our next question is from Meta Marshall with Morgan Stanley. Please proceed with your question.
Meta Marshall: Great. Thanks so much. Maybe a question for Sherri. I know you alluded to 6-inch yields kind of being a big portion of the gross margin increase. But just as we think about into the next year, how much of that improvement is really the yield improvements versus maybe some of the product mix or pricing? And then second question, just in Jim, a question for you. I know it was kind of asked about you know, the potential restrictions being put into place. But just you know, have you seen kind of a change in customer urgency to get product?
I know you are kind of sold out, but just in terms of a change in customer communication since over the past couple of weeks? Thanks.
Operator: Thanks, Meta, for your question.
Sherri R. Luther: So in terms of 6-inch yields, what I was mentioning is it is 6-inch cost structure. Because if you remember, we have talked about the fact that 6-inch wafers are--you know, we get 4x the amount of output from that from that wafer versus 3 inch. Right? 4 times, but it is at half the cost. So it is that cost structure that is beneficial to us. When I talk about, you know, what is ahead of us that will help drive, gross margin improvement, it is really that ramp of 6-inch Indium Phosphide products that will be beneficial to us because of the cost structure of 6 inch.
And I think, Jim, you should have Yeah, and I will just reiterate I said earlier that when we look at yields for 6-inch, the yields for 6-inch are actually higher than our 3-inch production. And so, again, it is more the benefit of the 6-inch is the cost structure cost structure benefit.
Operator: And then on the second part of your question around customer you know, sort of customer reaction to the to the recent writer's article.
James Robert Anderson: I would say, yeah, we have seen there is a number of customers that have reached out to us and have engaged in, you know, discussion around manufacturing and exploring different options around that. And so, yeah, I would say that has spurred some new customer demand and supply discussions. And so those discussions are ongoing. Great. Thank you.
Operator: Our next question is from Given Arya from Bank of America. Please proceed with your question.
Given Arya: Thanks for taking my questions. For the first 1, Jim, CPO for scale up, what is the timeline for Coherent? Is it second half of 27? Is it 2028? And then how broad is it? And what is the pushback from customers who do not want to adopt it early?
James Robert Anderson: Thanks, Vivek. As we have said this in the past. We continue to expect revenue from CPO for scale up applications to start to flow in the second half of calendar 27. And, yeah, that is been a consistent view for quite a while for us. And so the CPO that we are ramping right now will first go into scale out applications. And then that will continue to grow. And then scale up will kick in the second half of 27. And then you know, customers, I would say, within the scale up domain with customers, if we are not having a CPO discussion, they are at least considering or engage with us in NPO.
So I think almost every customer that we have, certainly the big strategic customers, are engaged with us in a discussion of CPO or NPO. And there is just a differing views by our customers depending on their architecture, whether they would prefer an NPO app, an NPO sort of form factor to start with or CPO. And some customers that were engaged with an NPO, I expect to eventually transfer to CPO further down the line, and some are choosing to go directly to CPO. And so it really depends on the particular customer and comes down to their specific architecture. Got it. Thank you.
Given Arya: And for my follow-up, maybe 1 more on gross margins. In the it is probably more nitpicking, but in the first half of the year, saw incremental gross margins that were more in the I think, mid forties or better. I think what you guided to for September is sort of in the low forties. I am just curious if there is anything specific for September and just broadly, how should we think about, incremental gross margin fall through for fiscal 27 given that you have kinda given us the bookends? For the year. Thank you.
Sherri R. Luther: Yeah. So, Vivek, when you think about you think about gross margin improvement going forward, it is really driving the initiatives that I talked about, right? Continued cost reduction pricing optimization. We will continue to focus on that. The timing of those benefits, it is it is gonna differ because it just depends on the initiatives and when they kick in. As we ramp throughout the rest of this year, as Jim mentioned, that $3 billion revenue number, by the end of FY 27, and you talked about the revenue opportunities there. He mentioned new products, right? He mentioned 1.6T, OCS, CPO, all these things kicking in, which are going be beneficial to our gross margin.
And so that will help drive improvements in gross margin as we move ahead. But when you talk about flow through on gross margin and what you can think about, the other thing that I would like to make sure that I call your attention to is that if you look at our operating expenses, in our Q1 guide that we provided at the midpoint of that guide, we are we are already below our operating our target model rather. So we gave a target model for OpEx just last year, in fact, of 18% for OpEx. And so the midpoint of our Q1 guide, we are already below that. And we are going to continue to drive operating efficiency.
We have made tremendous progress on the SG&A front, but there is more operating leverage that we will get out of R&D as well. So when you think about total flow through, you know, keep that in mind as well. I just wanna point that out because I expect that there is significant opportunity to drive even greater operating leverage for the reasons that I just stated. Thank you.
Operator: Our next question is from Michael Mani with Rosenblatt Securities. Please proceed with your question.
Michael: Great. Thanks, Jim. it is really good to see the expectation for CPO laser revenues in the fiscal second quarter because that would imply that you are either qualified or have line of sight to qualification and would kind of you know, go against some of the fuzz. I think that is not coming from Wall Street, but more coming from a substack saying you guys are having trouble with that laser. Just any more color on, like, the confidence that, you know, you will be ready for the customer to actually recognize revenue in that quarter and just progress that is been made recently? Thanks.
James Robert Anderson: Yeah. I am really pleased with the progress. I think the team's done a great job. I actually think our design on that particular laser is outstanding and has some significant technical advantages and production advantages. And, yeah, we have we have already started production wafers for those shipments in our December quarter, and that customer continues to tell us to please ship more as fast as possible. So, yeah, I think we feel really good about that. And but just as a reminder, it is not just lasers. Right?
We supply lasers, external laser modules, the different optical connectors, the fiber optic cable, the fiber attach unit. there is a there is a lot of content that we supply just beyond just the laser. But, certainly, laser is a key ingredient. Great.
Michael: Sounds good. Last question. You have mentioned already repeatedly about the LTAs, which gives you revenue visibility. My question is, does that also give you pricing visibility and specifically, you know, how far into the future do you think that prices of lasers will keep rising when you sort of weigh your LTAs and the and the amount of capacity that is been added and the potential for increasing competition may be coming from China. But your confidence sort of how far out you think before we have to worry about, you know, laser prices not going up anymore?
James Robert Anderson: Yeah. it is a good question, Michael. The so when we when we do LTAs, they almost always have not just a volume commitment, but agreed upon pricing as well. And so the pricing is set for I think, all or almost all of our LTAs out through the length of the LTA. Some of those are 3 years. Many of those go out through the rest of the decade. So that gives us great visibility on not just the volume that we need to go drive, but the pricing that we can expect as well. So it is it is good visibility from both those aspects. Thanks for taking the questions. Appreciate it. Thank you.
Operator: This concludes our Q and A session. I would like to turn the floor back over to Jim Anderson for closing comments.
James Robert Anderson: Yes. Thanks, operator, and thanks again for joining us on the call today. So we are certainly entering our fiscal 27 with great momentum exceptional customer demand, and really accelerating growth prospects given the capacity and the ramp in new growth platforms ahead of us. I think with our with our photonic technology and manufacturing scale, I think the company is just really well positioned moving forward. I just want to say thanks again to our employees, for their great work in fiscal 26 and to all of our customers, partners, and shareholders for their support. So thank you, and we will look forward to updating you again in another quarter.
Operator: This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
Should you buy stock in Coherent right now?
Before you buy stock in Coherent, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Coherent wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $419,408 ! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,348,694 !
Now, it's worth noting Stock Advisor's total average return is 966% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 19, 2026.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has positions in and recommends Coherent. The Motley Fool has a disclosure policy .
Coherent (COHR) Q4 2026 Earnings Call Transcript was originally published by The Motley Fool
长债回购缓解收益率压力
重要性5/5 高
覆盖财政部流动性操作、长端收益率和联储政策信号，并关联NVDA、MRVL等日报标的，具有较强的宏观传导价值。
中文摘要
核心结论
美国财政部扩大长期国债回购后，长端收益率压力暂时缓和，标普500指数和道指收高，但联储会议纪要仍保留通胀未降时继续收紧政策的可能。文章把当日市场表现与财政部流动性支持、利率预期及多只个股消息放在同一盘前综述中，宏观信号较个股催化更具解释力。
重要性评级
评级：5/5（高）。文章发布于日报窗口内，覆盖美债流动性、联储政策和NVDA、MRVL等相关标的，具有跨资产传导价值；部分个股信息只是新闻汇总，独立证据深度有限。
关键事实
- 文章发布于美东时间 08/19 19:15（UTC+8 08/20 07:15）。标普500收涨0.2%至7707.98点，道指涨0.2%至53463.05点，纳斯达克100跌0.2%至29426.02点，罗素2000涨0.5%。
- 08/20盘前标普500期货涨0.1%，纳斯达克100期货涨0.3%，道指期货上涨29点，约0.05%。
- 美国财政部宣布自 09/09 起，将10年至30年期国债回购规模提高至至少40亿美元，文章称规模约为此前水平的两倍，目标是改善长期国债市场深度和流动性。
- 30年期美国国债收益率此前触及5.31%，为 2007年以来高位；TLT（20年以上期美国国债交易所交易基金）当日上涨约1.5%。
- 7月28日至29日的联储会议纪要显示，多数与会者认为若通胀未下降，可能需要进一步收紧政策；部分官员认为金融条件尚不足以推动通胀回到2%。
- NVDA被报道正讨论参与人工智能数据标注初创公司Mercor的新一轮融资，后者估值约200亿美元；MRVL（马威尔）向谷歌母公司Alphabet授予最高约122亿美元的购股权。
- MRNA（莫德纳）与默沙东合作的黑色素瘤疗法达到三期试验主要终点；Lowe's将2026年销售指引调整为920亿美元，低于此前920亿至940亿美元区间的上限。
作者观点与证据
文章将股指上涨归因于收益率回落和财政部扩大回购计划，并引用LPL Financial观点称该措施可缓解市场压力，但难以单独解决长期利率问题。财政部公告和联储会议纪要提供了政策事实；个股部分来自新闻团队汇总，NVDA融资讨论、MRVL合作条款和MRNA试验进展的详细条件没有在本文中完整展开。
与相关标的的关系
NVDA和MRVL是文章元数据中的直接标的。NVDA还受到人工智能基础设施融资消息影响，MRVL的谷歌合作涉及潜在长期定制芯片收入。TLT代表长久期美债对收益率变化的敏感性；SPY（标普500指数交易所交易基金）和科技板块基金反映了收益率回落对风险资产的短期支撑。MRNA、默沙东和Lowe's属于文章列出的相关个股。
时效性与限制
文章发布于美东时间 08/19 19:15（UTC+8 08/20 07:15），盘前期货、收盘数据和政策消息处于不同时间截面。财政部回购规模是 09/09 起的计划，联储纪要反映 07/28—07/29 的会议讨论，不能单独代表最新利率决策。
后续跟踪
- 10年至30年期国债回购在 09/09 后的实际规模和市场流动性。
- 30年期国债收益率是否继续处于5%上方。
- 后续通胀数据对联储收紧预期的影响。
- NVDA、MRVL和MRNA相关合作或临床信息是否出现正式文件。
英文原文
US Stock Index Futures Climb As Yields Cool Off Amid Treasury Support — NVDA, MRNA, MRVL, LOWE In Focus
US Stock Index Futures Climb As Yields Cool Off Amid Treasury Support — NVDA, MRNA, MRVL, LOWE In Focus
Shashank Nayar
Thu, August 20, 2026 at 8:15 AM GMT+9 4 min read
- ^GSPC
+0.21%
- ^DJI
+0.22%
- ^RUT
+0.50%
- ^NDX
-0.22%
- SPY
+0.21%
- The S&P 500 ended 0.2% higher, while the Nasdaq 100 lost 0.2% and the Dow Jones Industrial Average added 0.2%.
- 10-year Treasury yields hovered near the highest levels since early 2025 on Tuesday.
- Bitcoin jumped as President Donald Trump pressed Congress to pass a key crypto bill.
The S&P 500 and Dow Jones indices ended higher on Wednesday, taking support from falling bond yields after the Treasury Department said it plans to boost buybacks of longer-dated bonds.
The S&P 500 ended 0.2% higher, while the Nasdaq 100 lost 0.2% and the Dow Jones Industrial Average added 0.2%. The Russell 2000, which tracks stocks with small market capitalizations, rose 0.5%.
See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox
S&P 500 futures were last up 0.1%, and Nasdaq-100 futures added 0.3%. Dow Jones Industrial Average futures rose 29 points, or 0.05%.
Among ETFs tracking benchmark indexes, the SPDR S&P 500 ETF (SPY) rose 0.4%, and Invesco QQQ Trust (QQQ) ended Wednesday 0.2% higher, while the SPDR Dow Jones Industrial Average ETF Trust (DIA) was up 0.3%.
Meanwhile, the VanEck Semiconductor ETF (SMH) dropped 0.8%, with Nvidia (NVDA), Micron Tech (MU) and Broadcom (AVGO) leading declines. The broader Vanguard Information Technology ETF (VGT) fell 0.4%.
Retail sentiment on Stocktwits for QQQ and DIA was 'bearish' with 'high' message volumes and was 'bullish' on the SPY.
US Market Drivers
Index
Move
Close
Dow Jones Industrial Average
0.2%
53,463.05
S&P 500
0.2%
7,707.98
Nasdaq 100
-0.2%
29,426.02
In an official release, authorities said that starting September 9, the U.S. Treasury will double the size of its liquidity-support buyback operations for government obligations maturing between 10 and 30 years, scaling them to $4 billion or more.
Officials highlighted that the aggressive step was taken to strengthen market depth and address emerging illiquidity across benchmark long-dated issues.
The intervention comes after intense pressure in debt markets earlier in the week, when the yield on the 30-year Treasury bond touched 5.31%—the highest borrowing rate for the U.S. federal government since 2007. The iShares 20+ Year Treasury ETF (TLT) gained about 1.5% on Wednesday.
"This is more of a band-aid than a panacea," Lawrence Gillum at LPL Financial told Bloomberg. "But it is a reminder that the Treasury Department is paying attention and will do whatever it can to keep yields from getting too high too quickly."
Fed officials at their July meeting pointed to the potential for higher rates unless inflation calms, minutes released Wednesday showed.
Story Continues
"Many participants assessed that policy tightening would likely be necessary if inflation did not decline," stated the summary of the meeting, held July 28-29. "Some participants commented that financial conditions might not currently be sufficiently restrictive to facilitate a return of inflation to 2 percent."
Key Trending Stocks
Nvidia Corp. (NVDA): The company is in discussions to back the artificial intelligence data-labeling startup Mercor in a new funding round that would value the three-year-old firm at $20 billion.
Moderna (MRNA): mRNA cancer treatment, developed with Merck (MRK), met the primary goal in a pivotal late-stage melanoma study.
Marvell Technology (MRVL): The company disclosed a formal commercial agreement with Google parent Alphabet (GOOG, GOOGL) that would give Google a warrant to buy roughly $12.2 billion worth of Marvell shares.
Lowe's Companies (LOWE): The company updated its 2026 outlook and now expects total sales of $92 billion compared to the earlier guidance range of $92 billion to $94 billion.
Steel and Aluminum Stocks: US steel stocks dropped after a report stated that the U.S. could halve tariffs on Canadian steel and aluminum.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Shashank Nayar has no position in any of the stocks mentioned in this article. StockTwits' news team content is for informational purposes only and is not intended as investment advice. For more, see our editorial policy . This article was originally published on StockTwits .
Related:
- Moderna Is Now S&P 500's No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
- MSTR Stock Climbs As Bitcoin Surges Past $69K For First Time Since June: Trump Urges Congress To Pass CLARITY Act
- TGT Stock Heads For Fourth Weekly Gains: Target's Turnaround Gains Traction, DA Davidson Says 'Earnings Power' Can Keep Rising
AI云扩张融资引发股价下挫
重要性5/5 高
直接覆盖NBIS，45亿美元融资与即时股价反应具有较强时效性，且换股结构影响潜在稀释；最终条款仍待正式文件。
中文摘要
核心结论
Nebius（NBIS）宣布拟私募发行45亿美元可转优先票据，资金用于数据中心、GPU采购和全栈人工智能云扩张，股价盘中一度下跌13.72%。融资可强化资本投入能力，但潜在换股、对冲解除和新票据转股条款可能带来股本稀释与价格压力，最终利率和转换条件尚未确定。
重要性评级
评级：5/5（高）。文章直接涉及NBIS，融资金额大且已有即时股价反应，融资结构对资金供给、潜在稀释和市场定价均有直接意义；来源为二次转载，正式定价文件尚未发布。
关键事实
- 文章发布于美东时间 08/19 14:15（UTC+8 08/20 02:15）。
- Nebius拟发行45亿美元可转换优先票据，其中27.5亿美元于2030年2月到期，17.5亿美元于2034年2月到期。
- 初始购买者另有增购选择权，分别为3.75亿美元和3亿美元，合计6.75亿美元。
- 公司计划把资金用于数据中心建设、GPU采购、全栈人工智能云开发、扩大数据中心规模及一般公司用途。
- 公司预计与部分2029年到期、票面利率2.00%的票据，以及2031年到期、票面利率3.00%的票据持有人进行换股，部分债务可能转换为A类股票。
- 文章称NBIS盘中下跌13.72%；拟议发行并不以旧票据换股完成为前提。
- 新票据的利率和转换条件将在定价时确定，旧票据持有人出售换股所得股票或解除对冲，可能压低A类股价格并影响新票据初始转换价格。
作者观点与证据
文章将融资用途描述为支持Nebius人工智能云基础设施扩张，同时强调资金筹集伴随换股、潜在稀释和市场供给压力。45亿美元金额、到期结构、资金用途和股价跌幅来自文章报道；转换价格、票面利率和最终发行规模尚未定价，因而关于稀释程度和价格影响的内容属于条件分析。
与相关标的的关系
NBIS是文章直接标的。资金若转化为数据中心和GPU产能，可能影响其人工智能云业务扩张速度；票据换股和旧持有人对冲调整则涉及A类股本结构与二级市场供给。融资规模本身不能代表项目回报或收入增速已经兑现。
时效性与限制
文章发布于美东时间 08/19 14:15（UTC+8 08/20 02:15），股价反应为盘中时点数据。本文来自GuruFocus二次转载，最终发行规模、利率、转换价格和换股安排需要以后续正式定价及监管文件确认。
后续跟踪
- 可转债最终票面利率、转换价格和发行规模。
- 旧票据换股的实际参与规模及潜在稀释比例。
- 数据中心建设、GPU采购和人工智能云收入兑现情况。
- 融资完成后NBIS现金消耗和资本开支变化。
英文原文
Nebius Stock Falls 14% on $4.5 Billion Convertible Offering
Nebius Stock Falls 14% on $4.5 Billion Convertible Offering
Renato Neves, CFA
Thu, August 20, 2026 at 3:15 AM GMT+9 1 min read
- NBIS
-9.87%
This article first appeared on GuruFocus .
Nebius Group ( NASDAQ:NBIS ), the Amsterdam-based AI cloud provider, fell 13.72% intraday after announcing a proposed private offering of $4.50 billion of convertible senior notes, split into $2.75 billion due February 2030 and $1.75 billion due February 2034. Initial purchasers get an option on a further $375 million and $300 million respectively.
Proceeds go to data center construction and build-out, developing the full-stack AI cloud, expanding the data center footprint, procuring GPUs, and general corporate purposes.
Alongside the offering, Nebius expects to agree exchanges with some holders of its 2.00% notes due 2029 and 3.00% notes due 2031, swapping a portion for Class A shares. Nebius states that those holders may sell the shares or unwind hedge positions, and that this could decrease the market price of the Class A shares and affect the initial conversion price of the new notes. The offering isn't contingent on those exchanges completing. Interest rates and conversion terms will be set at pricing.
个体化黑色素瘤疗法通过三期
重要性5/5 高
三期主要终点直接关联MRNA、MRK及医疗保健板块，样本量和风险下降数据较具信息量；总生存期与监管节点仍是关键验证环节。
中文摘要
核心结论
莫德纳（MRNA）与默沙东（MRK）的个体化新抗原信使核糖核酸疗法在高风险黑色素瘤三期临床试验中达到主要终点，联合方案较单用Keytruda（默沙东免疫治疗药物）改善无复发生存和无远处转移生存。文章将这一结果视为平台验证，但总生存期、监管申报和其他癌种试验仍需继续确认。
重要性评级
评级：5/5（高）。试验结果发布时间新，直接关系MRNA、MRK及医疗保健板块；样本量和主要终点信息较强，但详细数据、总生存期和监管进展尚未完整披露。
关键事实
- 文章发布于美东时间 08/19 09:22（UTC+8 08/19 21:22）。文中称MRNA早盘一度上涨93%至121.76美元，MRK上涨7%至144.60美元。
- 三期INTerpath-001试验评估Intismeran Autogene（个体化新抗原信使核糖核酸疗法）联合Keytruda，用于手术完全切除的高风险IIB至IV期黑色素瘤患者。
- 试验共纳入1137人，约三分之二接受联合方案，其余接受单用Keytruda；联合方案在无复发生存和无远处转移生存方面达到统计学显著且具有临床意义的改善。
- 试验未出现新的安全性问题，但仍将继续评估总生存期。
- 既往二期临床数据在五年时显示，联合方案使复发或死亡风险下降49%，远处转移或死亡风险下降59%。
- 公司计划在覆盖黑色素瘤、肺癌、膀胱癌、肾癌、胰腺癌和胃癌的9项二期及三期试验中继续研究该疗法。
- 文章称BioNTech（拜恩泰科）股价仅上涨约1%，XLV（医疗保健选择行业交易所交易基金）早盘涨约2%，单一生物科技公司的大幅波动对宽基行业基金的影响有限。
- 文中还提到MRNA期权全链条看跌看涨比率为0.46，该数据反映文章发布时的市场情绪，不构成对后续走势的判断。
作者观点与证据
作者认为这是首个通过三期临床主要终点的个体化信使核糖核酸癌症疗法结果，能够增强市场对莫德纳平台和默沙东肿瘤合作的信心。试验样本量、主要终点和既往二期数据构成支持；“平台得到验证”和对其他癌种的外推属于作者或公司叙事，不能替代总生存期、完整统计数据和监管审查。
与相关标的的关系
MRNA和MRK是事件直接相关标的，主要影响路径是临床成功概率、肿瘤产品商业化潜力和合作双方的研发价值。XLV是元数据中的直接标的，但其持仓分散，单个生物科技事件对基金净值的传导较弱。BioNTech可能获得行业情绪层面的关联影响，文章明确指出其并未参与该试验。
时效性与限制
文章发布于美东时间 08/19 09:22（UTC+8 08/19 21:22），股价数据来自早盘或盘中时点。当前主要终点结果尚未等同于总生存期结果或监管批准，详细试验数据、国际医学会议披露和监管申报时间仍未确定。
后续跟踪
- 总生存期随访结果及完整统计数据。
- 国际医学会议上的详细试验披露和监管申报进度。
- 其他8项相关临床试验的入组、读出和安全性。
- MRNA、MRK及XLV对事件信息的后续价格反应。
英文原文
Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial
Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial
David Moadel
Wed, August 19, 2026 at 10:22 PM GMT+9 4 min read
- MRK
+12.60%
- MRNA
+176.97%
- XLV
+3.51%
- NVDA
-0.99%
- BNTX
+21.96%
Quick Read
- Moderna surges 93% and Merck gains 7% after their cancer combo becomes the first personalized mRNA therapy to clear a Phase 3 trial.
- BioNTech, the other major mRNA cancer developer, rose just 1% while the broad XLV ETF gained only 2% as Moderna's win diluted across holdings.
- Phase 2b data showed a 49% reduction in recurrence or death, and the combination now advances across nine trials targeting six cancer types.
- Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today .
Shares of Moderna ( NASDAQ:MRNA ) are rocketing higher Wednesday morning, with the stock up 93% to $121.76 in early Wednesday trading after the company and partner Merck ( NYSE:MRK ) announced that their Phase 3 melanoma trial met its primary endpoint. Merck stock is up 7% to $144.60 on the news.
hapabapa / iStock Editorial via Getty Images The catalyst is the first positive Phase 3 readout for a personalized mRNA cancer therapy, an outcome that validates a platform Moderna has spent years building. Moderna shares closed Tuesday at $62.96, down 2% on the session, and the stock has already climbed 114% year to date through Tuesday's close.
Merck stock closed Tuesday at $135.17 and is up 30% year to date through Tuesday's close. If early levels hold, Moderna is on track for its biggest ever single-day gain and could open at more than two-year highs.
Phase 3 Melanoma Trial Delivers on Primary Endpoint
The Phase 3 INTerpath-001 trial tested Intismeran Autogene alongside Merck's immunotherapy Keytruda in patients with high-risk stage IIB-IV melanoma whose tumors had been completely removed by surgery. The combination produced statistically significant and clinically meaningful improvements in recurrence-free survival and in distant metastasis-free survival compared with Keytruda alone.
Enrollment reached 1,137 patients, with two-thirds receiving Intismeran plus Keytruda and the remainder receiving Keytruda alone. No new safety concerns emerged, and the trial will continue to assess overall survival.
Dean Y. Li, President of Merck Research Laboratories, summed up the results succinctly:
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today .
These first Phase 3 findings for Intismeran in combination with Keytruda as adjuvant therapy reinforce the promise of a more personalized approach to cancer treatment. We believe individualized neoantigen therapies have the potential to redefine how patients with completely resected stage IIB-IV melanoma are treated.
Story Continues
The results reinforce the earlier Phase 2b Keynote-942 study, where at five years the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% versus Keytruda alone. The companies are now exploring the approach across nine Phase 2 and Phase 3 trials covering melanoma, lung, bladder, kidney, pancreatic and gastric cancers.
Peers Trade Higher, but the mRNA Read-Across Is Uneven
Pfizer ( NYSE:PFE ) stock is up 1% to $27.50 in early Wednesday trading, and Pfizer shares are up 15% year to date through Tuesday's close. The pharma giant benefits indirectly from renewed enthusiasm around oncology combinations, though it has no direct role in the trial.
BioNTech ( NASDAQ:BNTX ) is the more interesting peer read. Its shares rose 1% Tuesday to close at $92.75 and are down 3% year to date through Tuesday's close. As the other major mRNA cancer developer, BioNTech has been roughly flat in 2026 while Moderna has run hard, and today's validation of individualized neoantigen therapy could reset that narrative.
XLV ETF Reflects a Diluted Move
The Health Care Select Sector SPDR Fund ( NYSEARCA:XLV ) is up 2% to $172.36 in early Wednesday trading, and the ETF is up 11% year to date through Tuesday's close. As a broad healthcare sector fund holding dozens of large-cap names, any single biotech carries a small weight.
That means Moderna's outsized jump translates into a modest lift at the fund level, even with Merck's participation adding weight to the move. Investors seeking direct exposure to mRNA oncology innovation would need the underlying names rather than a diversified sector fund.
What to Watch Next
Retail sentiment on Moderna tracked very bullish heading into the U.S. session, and Moderna options flow is skewed to calls, with the full-chain put/call ratio at 0.46. The Wall Street consensus price target of $50.84 now sits far below the indicated open, so revisions are likely.
MRNA Analyst Ratings — 24/7 Wall St. The next data checkpoints will come at an upcoming international medical meeting, where the companies plan to present detailed trial results and discuss regulatory submissions. Traders could look for signs that the combination expands into the other tumor types under active study.
Investors may want to keep an eye on whether Moderna shares hold their early gains through the close. A durable move above $120 could confirm a genuine platform re-rating rather than a one-day squeeze.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today .
Contact editorial@247wallst.com for any questions or corrections.
谷歌扩大马威尔AI芯片合作
重要性4/5 中高
合作直接涉及MRVL且条款金额和收入里程碑具有增量价值，但文章为二次分析，正式合同和实际收入仍待验证。
中文摘要
核心结论
马威尔科技（MRVL）扩大与谷歌的人工智能定制芯片合作，并获得最高约121.8亿美元的购股权安排，但该金额不是谷歌一次性投入，绝大部分购股权需以马威尔实现合格收入后分批归属。文章认为，收入里程碑比 headline 金额更能衡量合作价值，同时竞争、执行和股东稀释仍是主要限制。
重要性评级
评级：4/5（中高）。文章直接覆盖MRVL，合作消息新且金额大，提供收入归属机制和竞争格局等增量信息；来源为二次财经分析，正式合同细节和收入确认尚未在文中完整披露。
关键事实
- 文章发布于美东时间 08/19 17:15（UTC+8 08/20 05:15）；消息后MRVL盘前一度上涨超过11%，博通下跌超过2%。
- 合作涉及谷歌TPU（张量处理器）生态，包括人工智能推理加速器、存储与网络产品、内存接口控制器和近内存计算。
- 谷歌获得最多5897万股马威尔股份的购股权，行权价为每股206.58美元，最大名义价值约121.8亿美元；文章强调谷歌并未承诺预先投入这笔金额。
- 大部分购股权与马威尔从谷歌取得的合格收入挂钩，每实现5亿美元合格收入，便有一批购股权归属；收入未达到门槛时，部分购股权可能失效。
- 马威尔此前预计2029财年定制芯片收入超过100亿美元，并预计今年数据中心收入增长约50%。
- 2024年12月，马威尔曾与亚马逊云服务达成类似安排，涉及418万股、行权价87.78美元，并与收入表现挂钩，期限延伸至2030年1月。
- 谷歌与博通已有定制TPU和网络合作，文章判断马威尔仍需在技术、价格、产能和量产执行上取得更多业务。
作者观点与证据
作者将收入挂钩的归属机制视为合作价值的可追踪指标，认为谷歌继续扩大人工智能基础设施投入，有利于马威尔进入更大的定制芯片市场。证据来自合作条款、历史亚马逊安排、公司收入目标和盘前市场反应；关于合作将形成长期增长驱动的部分属于文章判断，尚未由已确认收入验证。
与相关标的的关系
MRVL是文章直接标的。合作可能扩大其在谷歌人工智能基础设施中的芯片、网络和光互联内容，但购股权归属也会带来潜在股本稀释。博通是重要竞争方，谷歌采用多供应商并不等于马威尔将获得确定的采购规模。
时效性与限制
文章发布于美东时间 08/19 17:15（UTC+8 08/20 05:15），市场反应为盘前时点数据。121.8亿美元是购股权的最大名义价值，实际价值取决于收入门槛和行权；文章未提供完整合同、确认收入或具体归属时间表。
后续跟踪
- 马威尔来自谷歌的合格收入及5亿美元里程碑进展。
- 购股权实际归属数量和潜在稀释比例。
- 谷歌与博通、马威尔之间的定制芯片分工变化。
- 马威尔数据中心收入增长和利润率表现。
英文原文
Marvell Technology (MRVL) Expands Google AI Partnership: What Investors Need to Know
Marvell Technology (MRVL) Expands Google AI Partnership: What Investors Need to Know
Vardah Gill
Thu, August 20, 2026 at 6:15 AM GMT+9 6 min read
- MRVL
+9.85%
Marvell Technology, Inc. (NASDAQ: MRVL ) has expanded its partnership with Google to develop custom chips for AI infrastructure, strengthening its position in the growing custom-silicon market. The agreement covers several areas linked to Google's Tensor Processing Unit ecosystem, including AI inference accelerators, storage and networking products, memory interface controllers, and near-memory computing.
Alongside the commercial agreement, Marvell issued Google a warrant to buy up to 58.97 million Marvell shares at $206.58 each. If fully exercised, the warrant would be worth about $12.18 billion. The headline figure is important, but it needs some context because Google is not committing $12.18 billion upfront. Most of the warrants will vest only as Marvell generates revenue from Google over the coming years.
Investors reacted strongly to the news, with Marvell Technology, Inc. (NASDAQ:MRVL) shares gaining more than 11% in premarket trading. Broadcom, Google's existing custom-chip partner, fell more than 2%.
Marvell Technology (MRVL) Expands Google AI Partnership: What Investors Need to Know Photo from Marvell website
Bull Case: A Long-Term Growth Opportunity
The most important part of the deal may be the way the warrant is structured. Most of the shares are linked to actual revenue from Google rather than simply vesting over time. That gives investors a fairly clear way to track how the relationship develops.
Every $500 million in qualifying revenue allows another tranche to vest. If Marvell continues winning business from Google, more of the warrant becomes valuable. If the revenue does not materialize, much of the warrant may never vest. In that sense, the agreement creates a direct link between Google's spending on Marvell's products and the potential value of the warrant.
The deal also gives Marvell a larger role in a market that is becoming increasingly important to major cloud companies. Google, Amazon, and other hyperscalers are investing heavily in custom chips as they look for ways to build AI infrastructure that is better suited to their own workloads and less dependent on general-purpose GPUs.
Google's continued investment in its TPU ecosystem fits directly into this trend. The fact that Marvell will work on areas such as memory controllers and near-memory computing suggests the relationship goes beyond a single chip program and could develop into a broader role within Google's AI infrastructure.
There is also a useful precedent. In December 2024, Marvell reached a similar warrant agreement with Amazon Web Services covering 4.18 million shares at an exercise price of $87.78. That warrant was also linked to revenue generated from AWS and remains tied to performance through January 2030.
Story Continues
The Google agreement is much larger. The potential share count is more than 14 times the size of the AWS warrant, while the exercise price is also substantially higher. That difference suggests the potential scale of the Google relationship is considerably greater.
Marvell Technology, Inc. (NASDAQ:MRVL) was already positioned for strong growth in AI infrastructure before this announcement. The company has previously targeted more than $10 billion in custom-chip revenue by fiscal 2029 and expects data-center revenue to grow by roughly 50% this year. If those targets are achieved, the Google agreement could strengthen an existing growth story rather than create an entirely new one.
The deal could also improve Marvell's position against Broadcom. Broadcom already has a long-term relationship with Google covering custom TPU development and networking through 2031. Google's decision to expand its work with Marvell alongside Broadcom suggests that the company is willing to use multiple suppliers as its AI infrastructure requirements grow. For Marvell, gaining a larger share of Google's spending could become a meaningful source of revenue over several years.
The $12.18 Billion Figure Can Be Misleading
The biggest risk is that investors may focus too heavily on the $12.18 billion headline figure. That amount represents the maximum potential value of the warrant, not a guaranteed investment by Google.A
Most of the shares will only vest when Marvell Technology, Inc. (NASDAQ:MRVL) generates enough qualifying revenue. If Google's purchases remain below the required thresholds, a significant portion of the warrant could expire without being exercised.
Competition is another concern. Broadcom already has a significant relationship with Google and is involved in Google's custom TPU development and AI networking. Marvell still has to prove that it can win additional business on the basis of technology, pricing, manufacturing capacity, and execution.
Winning a custom-chip contract is also not the same as generating strong profits from it. Marvell Technology, Inc. (NASDAQ:MRVL) will need to move from development and design wins to large-scale production while maintaining attractive margins. That process can require significant investment, and revenue growth does not automatically translate into equivalent growth in earnings.
There is also a risk that the stock has already priced in much of the good news. An 11% premarket jump shows that investors are expecting the Google relationship to become a meaningful growth driver. That creates a higher bar for Marvell in the quarters ahead.
Conclusion
The Google agreement is a meaningful development for Marvell Technology, Inc. (NASDAQ:MRVL) because it gives the company a broader role in Google's AI infrastructure while potentially creating a substantial source of custom-chip revenue through 2033.
The $12.18 billion warrant should not be treated as a guaranteed investment. Its value depends largely on how much business Google ultimately gives Marvell. That is also what makes the structure interesting for investors: the revenue-linked vesting provides a clear way to measure whether the partnership is actually delivering.
The biggest positives are Google's growing AI infrastructure needs, Marvell's expanding custom-silicon business, and the potential for the company to take a larger share of hyperscaler spending. The main risks are competition from Broadcom, execution challenges, shareholder dilution, and the possibility that the market has already priced in strong growth.
Overall, the deal strengthens the long-term bull case for Marvell, but investors should focus less on the $12.18 billion headline and more on the actual revenue Marvell generates from Google. The progress toward those $500 million revenue milestones will be the clearest indication of whether this becomes a major long-term growth driver for the company.
While we acknowledge the potential of MRVL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
Disclosure: None. This article is originally published at Insider Monkey .
FDA加速批准TUDRIQEV黑色素瘤疗法
重要性4/5 高
FDA加速批准为Replimune带来明确的监管与商业化节点，且文章提供了缓解率、持续时间和安全性等关键临床数据。消息发布已有约两周，批准仍依赖验证性三期试验，时效性和证据完备度低于即时监管公告。
中文简要摘要
完整摘要达到当日时间预算，以下保留已完成的模型简要摘要。
Replimune于08/06（未给出具体时刻）宣布，美国FDA加速批准TUDRIQEV（vusolimogene oderparepvec-wtpg）联合纳武利尤单抗，用于既往抗PD-1方案进展、不可切除晚期皮肤黑色素瘤成人患者。IGNYTE疗效可评估人群为91人，客观缓解率24.2%，缓解持续时间中位数14.1个月；140名患者中35%出现严重不良反应。该批准基于缓解率和缓解持续时间，后续能否维持取决于正在进行的IGNYTE-3三期验证试验。消息直接关系Replimune（纳斯达克：REPL），但原文为公司新闻稿，且距本次检索约两周，需结合后续监管与商业化数据判断。
英文原文
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen | Replimune Group Inc.
Skip to main navigation
Release Details
Press
##
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
August 6, 2026
PDF Version
Broad label to address high unmet need in advanced melanoma
Replimune will host conference call on August 6, 2026 at 4:30 p.m. ET .
WOBURN, Mass. , Aug. 06, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ( FDA ) has granted accelerated approval for TUDRIQEV TM (vusolimogene oderparepvec-wtpg), previously referred to as RP1 , in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen.This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent on verification of clinical benefit in a confirmatory trial(s).
The IGNYTE trial enrolled 140 patients with 91 patients with at least one non-injected lesion included in the efficacy-evaluable population. In this population, TUDRIQEV plus nivolumab achieved an objective response rate (ORR) of 24.2%, with a median duration of response of 14.1 months. Treatment was well tolerated with mostly mild-to-moderate adverse events. The patient population included patients with Stage 4 disease (80%), prior anti-PD-1 adjuvant treatment (13%), PD-L1 negative status (54%), lung (45%) and liver lesions (24%). The IGNYTE study data were published in the Journal of Clinical Oncology and are available here .
“This is a transformative moment for Replimune , marking years of pioneering research to bring TUDRIQEV to patients desperately in need of new treatment options for advanced melanoma,” said Sushil Patel , Ph.D., CEO of Replimune . “We are deeply grateful to the melanoma community, including patients and investigators who participated in the clinical trial, for their tremendous support of this approval. We also would like to thank the FDA for recognizing the urgency to get this therapy to patients. Replimune is now focused on critical activities to deliver TUDRIQEV to as many patients as possible.”
There are limited treatment options for advanced melanoma, and more than half of patients experience progression within six months of treatment on immune checkpoint inhibitors like anti-PD-1 therapy. These patients face a poor prognosis, with a median overall survival of less than one year following progression.
“Advanced melanoma patients have few options after anti-PD-1 therapy and face high morbidity and poor survival outcomes,” said Michael K. Wong , MD, PhD, primary investigator of the IGNYTE study and Former Physician in Chief and Professor of Oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY . “With the approval of TUDRIQEV, we have a potent oncolytic immunotherapy that can be used in a broad population, including BRAF-naïve or pretreated, and adjuvant relapsed patients. Importantly, the therapy in combination with nivolumab drives immune activation with a favorable risk-benefit profile and can be injected into superficial and visceral lesions.”
“The approval of RP1 in combination with nivolumab is a meaningful step forward for patients with advanced melanoma who have failed to benefit from immunotherapy,” said Sam Guild , President of AIM at Melanoma. “Every year, more than 8,500 people die of melanoma in the U.S ., and new treatment options are urgently needed.”
TUDRIQEV combined with nivolumab was well-tolerated. The most common (incidence ≥ 10%) adverse reactions in patients treated with TUDRIQEV combined with nivolumab were nausea, diarrhea, vomiting, constipation, decreased appetite, abdominal pain, fatigue, pyrexia, chills, injection site reaction, influenza like illness, infections, musculoskeletal pain, arthralgia, headache, dizziness, cough, dyspnea, rash, pruritic and hemorrhage. 1 Most treatment-related adverse reactions were grade 1 and 2 and transient. 1 There were no grade 4 or 5 common adverse events. See additional Important Safety Information below.
TUDRIQEV is administered via direct intratumor injection into superficial and deep and/or visceral lesions 1 . For deep/visceral tumors, administration is guided by imaging technology. 1 The recommended dose of TUDRIQEV is based on tumor size. 1
To verify the clinical benefit of TUDRIQEV, a confirmatory Phase 3 trial, IGNYTE-3, is ongoing and assessing TUDRIQEV in combination with nivolumab (NCT06264180). For additional information about the trial, please visit https://replimune.com/clinical-trials/ignyte-3/ .
Replimune is committed to helping patients in the U.S . with advanced melanoma gain access to treatment with TUDRIQEV. Eligible patients who are prescribed TUDRIQEV will have access to ReplimuneConnect Plus , a comprehensive program offering information on access, reimbursement and financial support.
Webcast Details
Replimune will host a webcast featuring members from the management team to discuss today’s developments at 4:30 p.m. ET on Thursday, August 6, 2026 .
Listeners can register for the webcast via this link . Analysts wishing to participate in the question and answer session should use this link . A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
About Melanoma
Melanoma is the fifth most common cancer, with approximately 105,000 new cases estimated in the U.S . in 2025, and the most lethal form of skin cancer, accounting for nearly 8,500 deaths annually. Standard of care therapy includes treatment with immune checkpoint blockade, to which approximately half of patients will not respond or will progress after treatment. Melanoma is considered advanced when the cancer spreads beyond the primary tumor to other parts of the body.
About IGNYTE
IGNYTE (NCT03767348) is an open-label, multicenter Phase 1/2 study evaluating the safety and efficacy of vusolimogene oderparepvec as monotherapy or in combination with nivolumab in adult patients with advanced solid tumors, including a registrational cohort of patients with advanced melanoma with confirmed progression on an anti-PD-1 containing regimen treated with vusolimogene oderparepvec plus nivolumab.
The anti-PD-1 failed melanoma registrational cohort included 140 patients who received vusolimogene oderparepvec plus nivolumab after confirmed progression while being treated for at least eight weeks with anti-PD-1 based therapy, with or without anti-CTLA-4. Of the 140 patients, 91 patients with at least one noninjected lesion were included in the efficacy-evaluable population.
About TUDRIQEV TM (vusolimogene oderparepvec-wtpg)
TUDRIQEV (vusolimogene oderparepvec-wtpg) is a genetically modified herpes simplex virus, type 1 (HSV-1) oncolytic viral therapy that encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus with the R sequence deleted (GALV-GP-R–) and human granulocyte macrophage colony-stimulating factor (GM-CSF). The genes encoding the HSV-1 neurovirulence factor ICP34.5 and the transporter associated with antigen presentation inhibitor ICP47 are deleted from TUDRIQEV. TUDRIQEV preferentially replicates within the tumor leading to tumor lysis, release of tumor and viral antigens, proinflammatory molecules, and infiltration of T cells. The GALV-GP-R– expressed by TUDRIQEV increases direct tumor killing and the GM-CSF expressed by TUDRIQEV is intended to activate and mature dendritic cells and monocytes. In the anti-PD-1 resistant setting, TUDRIQEV and nivolumab in combination may promote anti-tumor immune response.
INDICATION
TUDRIQEV (vusolimogene oderparepvec-wtpg) is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions Accidental Exposure to TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients. Should accidental exposure occur, clean the affected area. Herpetic Infection or Reactivation: Assess and treat suspected herpetic lesions as clinically warranted. Visceral Injury: Monitor patients for signs and symptoms of visceral injury during and after TUDRIQEV administration and manage accordingly.
Adverse Reactions
Serious adverse reactions occurred in 35% of 140 patients who received TUDRIQEV in combination with nivolumab including 2 patients each with arthralgia, hypophysitis, immune-mediated enterocolitis, and pyrexia. Adverse reactions leading to permanent TUDRIQEV discontinuation occurred in 2.9% of 140 patients and were 1 each of amylase increased, lipase increased, myocarditis, and pneumonitis.
Most common non-laboratory adverse reactions (incidence ˃ 10%) are fatigue, pyrexia, chills, musculoskeletal pain, nausea, diarrhea/colitis, injection site reaction, headache, cough, influenza like illness, vomiting, pruritus, arthralgia, asthenia, constipation, decreased appetite, dizziness, skin/superficial infection, and dyspnea.
Drug interactions :
Antivirals: delay TUDRIQEV administration for 72 hours.
Special Populations
Females and Males of Reproductive Potential: Advise females of reproductive potential, and males with a female partner of reproductive potential to use effective contraception during TUDRIQEV treatment and for 90 days after the last dose.
Please report any adverse event or product quality complaint related to a Replimune product by calling 1-877-375-0095 . If you prefer, you may contact the U.S. Food and Drug Administration ( FDA ) directly. Visit www.fda.gov/medwatch or call 1-800- FDA -1088.
Please click here for full Prescribing Information, including Patient Information.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies, including the Company’s first commercially available product TUDRIQEV TM (vusolimogene oderparepvec-wtpg), approved under accelerated approval by the U.S. Food and Drug Administration in combination with nivolumab for the treatment of adults with advanced melanoma who experienced disease progression on a PD-1 antibody-based regimen. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response. Upon intratumor injection, RPx causes direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens, alteration of the tumor microenvironment, and when dosed in combination with an immune checkpoint inhibitor immunotherapy, it may ignite a systemic anti-tumor response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information on Replimune, please visit www.replimune.com and follow us on social media at LinkedIn and X .
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs, sufficiency of any resulting data), regulatory applications and related submission contents and timelines, the timelines or outcomes related to litigation, including any rehearings or appeals of decisions in any such proceedings, and our ability to execute on our strategic or financial initiatives, our estimates regarding future expenses, capital requirements and needs for additional financing, and potential commercial viability, and potential reimbursement and utilization of TUDRIQEV involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Our ability to maintain TUDRIQEV’s accelerated approval and to continue commercialization of TUDRIQEV may be contingent on verification of clinical benefit in a confirmatory trial(s). Other forward looking statements may be identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE-3, our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune, Inc.
917.548.1582
media@replimune.com
[i] TUDRIQEV Prescribing Information. Last updated: 08/26.
Oil Market Report - August 2026
重要性未评级
中文事实摘录
- IEA称，2026年全球石油需求预计下降160万桶/日；2026年第三季度需求收缩预计为280万桶/日，第四季度转为增长约58万桶/日。
- IEA称，7月全球石油供应环比增加240万桶/日至101.5百万桶/日，但仍较上年低630万桶/日，海湾地区仍有830万桶/日供应关闭。
- IEA称，7月全球观测石油库存减少6900万桶，库存低于79亿桶；7月北海Dated原油月末价格为96.80美元/桶，报告撰写时约92美元/桶。
- IEA称，霍尔木兹海峡在7月初再次实质关闭，海湾及里海出口中断使三季度全球石油供需缺口预测上修至180万桶/日。
本地未取得可读全文：HTTP 403。可使用上方“打开原文”核查。
Marvell IR：Q2 FY2027财报电话会与2026 Investor Day
重要性未评级
发布时间早于日报 5 天摘要窗口。
中文事实摘录
文章摘要达到当日时间预算，本次保留新闻索引与来源，不阻断日报生成；如有可读归档原文，可从下方原文区查看。
英文原文
IR Calendar
Upcoming Events
Aug 27, 2026 1:45 pm PDT
Q2 2027 Marvell Technology, Inc. Earnings Conference Call
Interested parties may join the live conference call without operator assistance at Call me™ (link will be active approximately 30 minutes before the call) to receive an instant automated callback. To join the call with operator assistance, please dial 1-877-407-8291 or 1-201-689-8345 .
A replay of the call can be accessed by dialing 1-877-660-6853 or 1-201-612-7415, passcode 13762036 until Thursday, September 3, 2026.
Oct 6, 2026
Marvell Investor Day 2026
Marvell will host its Investor Day the morning of Tuesday, October 6, 2026, in New York City
Past Events
Jun 3, 2026 2:40 pm PDT
BofA Securities 2026 Global Technology Conference
Jun 2, 2026 3:50 pm PDT
2026 Evercore Global TMT Conference
May 27, 2026 1:45 pm PDT
Q1 2027 Marvell Technology, Inc. Earnings Conference Call
Mar 17 – Mar 19, 2026
OFC 2026
Mar 5, 2026 1:45 pm PDT
Q4 2026 Marvell Technology, Inc. Earnings Conference Call
View All Past Events
-
email Email Alerts
-
location_city Company Profile
-
contact_page Contacts
-
rss_feed RSS News Feed
-
account_tree Sitemap
-
accessibility Accessibility Statement
Company
-
Awards
-
Industry Associations
-
Trade Compliance
-
Trademarks
-
The Marvell Code
Support
-
Driver Downloads
-
Customer Portal Login
-
Support by Product
-
Marvell Concern Line
Careers
-
University Recruiting
-
Jobs at Marvell
Worldwide
-
English
-
中文 (Chinese)
-
日本語 (Japanese)
-
-
-
-
-
-
Copyright © 2026 Marvell, All rights reserved.
-
Terms of Use
-
Privacy Policy
-
Contact
Binance USDS-M Futures persisted market snapshot
重要性未评级
这是 Binance BTCUSDT 行情原始快照，不是文章，且没有出版时间、事件背景或研究叙事。
中文事实摘录
文章摘要达到当日时间预算，本次保留新闻索引与来源，不阻断日报生成；如有可读归档原文，可从下方原文区查看。
英文原文
Binance USDS-M Futures persisted market snapshot
{"closeTime":1787193581199,"count":5729971,"firstId":7977970069,"highPrice":"70450.00","lastId":7983720657,"lastPrice":"69367.30","lastQty":"0.023","lowPrice":"64131.30","openPrice":"64364.80","openTime":1787107140000,"priceChange":"5002.50","priceChangePercent":"7.772","quoteVolume":"22764892455.05","symbol":"BTCUSDT","volume":"337509.964","weightedAvgPrice":"67449.54"}
金十快讯
摩根大通警告美国财政部回购债券存在信誉风险
摩根大通策略师称，财政部至少将长期国债回购规模扩大一倍；若缺少财政整顿，期限溢价和收益率可能上升；其提到美国国债规模已突破40万亿美元、财政赤字约占经济6%。
美国驻以色列大使称特朗普可能考虑对伊朗采取军事行动
据阿拉比亚电视台转述，若伊朗拒绝放弃核与浓缩铀相关目标并拒绝重新开放霍尔木兹海峡，特朗普可能考虑采取军事行动。
特朗普宣布对伊朗采取“史上最严厉”的经济制裁措施
特朗普称将对伊朗实施前所未有的经济制裁和孤立，并要求停止石油走私、互换额度、现金转账、船舶注册和空壳公司等活动；向伊朗提供救助的国家将面临经济后果。
国际油价19日上涨
纽约9月轻质原油期货收于85.83美元/桶，涨1.05%；10月布伦特原油收于91.62美元/桶，涨0.66%。
美联储工作人员：经济展望略显疲弱，通胀风险偏上行
工作人员预计下半年总体通胀回落、核心通胀小幅放缓；相较6月预测，经济活动展望略显疲弱，就业和实际GDP增速风险偏下行，通胀风险偏上行。
美联储会议纪要提及 AI 股票估值与国债波动风险
部分与会者关注AI基础设施融资脆弱性、高估值企业盈利预期下修引发资产重定价，以及美国国债价格波动对金融体系的影响。
美联储会议纪要：若通胀未降温，许多官员认为有必要进一步收紧政策
会议纪要称，许多与会者认为若通胀无法降至2%目标，政策可能需要进一步收紧；数名政策制定者在7月会议上倾向加息。
其余快讯（25）
A股人形机器人概念走弱
现货黄金回落至4490美元下方
韩国 KOSPI 日内上涨6%
澳大利亚7月失业率升至4.5%，就业人数减少1.58万人
创新药板块高开，疫苗主题 ETF 走强
瑞穗：日本贸易逆差短期内或持续
A股开盘上涨，港股恒指与科指高开
中国央行逆回购到期，当日净回笼3274亿元
人民币中间价：美元兑人民币报6.7808
中国一年期、五年期 LPR 均维持不变
上海黄金交易所黄金、白银 T+D 早盘上涨
韩国交易所启动 KOSPI 侧车机制，暂停程序化买入
LME三个月期铜盘中下探后反弹，库存增加
Stripe 宣布与 OpenRouter 达成收购协议
OpenAI 称 ChatGPT 注册、登录功能中断并修复中
日本7月出口同比增长23.2%，半导体设备出口增长49.1%
科技要闻：三星代工价格、SK海力士回购与 CoWoS 供需
扩大美债回购后亚洲股指期货走高
CME：美联储9月维持利率不变概率为67.3%
美国 CFTC 就 AI 算力期货征求公众意见
特朗普再次敦促美联储降息
美联储会议纪要未出现支持降息的观点
民调涉及特朗普家族加密货币项目与政策影响观感
阿联酋宣布暂停与伊朗的贸易、商业及金融交易
美股周二收跌，半导体股走弱
A股人形机器人概念走弱
快讯正文
中大力德、正裕工业连续两日跌停，宇树科技跌超15%，晋拓股份、卧龙电驱、埃斯顿、上纬新材跌幅超过7%。
现货黄金回落至4490美元下方
快讯正文
现货黄金回落至4490美元/盎司下方，日内跌0.73%；此前金十快讯记录其曾站上4500美元/盎司。
韩国 KOSPI 日内上涨6%
快讯正文
韩国KOSPI指数日内上涨6.00%，报6861.17点。
摩根大通警告美国财政部回购债券存在信誉风险
快讯正文
摩根大通策略师称，财政部至少将长期国债回购规模扩大一倍；若缺少财政整顿，期限溢价和收益率可能上升；其提到美国国债规模已突破40万亿美元、财政赤字约占经济6%。
美国驻以色列大使称特朗普可能考虑对伊朗采取军事行动
快讯正文
据阿拉比亚电视台转述，若伊朗拒绝放弃核与浓缩铀相关目标并拒绝重新开放霍尔木兹海峡，特朗普可能考虑采取军事行动。
澳大利亚7月失业率升至4.5%，就业人数减少1.58万人
快讯正文
7月季调后失业率4.5%，预期4.4%、前值4.4%；就业人数减少1.58万人，预期1.5万人；全职就业增加1.63万人，兼职就业减少3.22万人。
创新药板块高开，疫苗主题 ETF 走强
快讯正文
A股创新药板块大幅高开，多只个股涨停；金十称前一夜默沙东与莫德纳宣布联合研发黑色素瘤皮肤癌疫苗在大型试验中达到目标。
瑞穗：日本贸易逆差短期内或持续
快讯正文
瑞穗证券经济学家称，能源价格高企和霍尔木兹航运限制可能继续推高日本进口成本；日本政府公布7月贸易逆差6345亿日元。
A股开盘上涨，港股恒指与科指高开
快讯正文
A股开盘：沪指涨0.33%，深证成指涨1.03%，创业板指涨1.27%；港股开盘：恒指涨1.11%，科指涨1.69%。
中国央行逆回购到期，当日净回笼3274亿元
快讯正文
中国央行8月20日不开展逆回购操作，因3274亿元隔夜逆回购到期，当日实现净回笼3274亿元。
人民币中间价：美元兑人民币报6.7808
快讯正文
8月20日中间价：美元/人民币6.7808，较前一日下调46点；欧元/人民币7.8815，100日元/人民币4.2636。
中国一年期、五年期 LPR 均维持不变
快讯正文
中国央行公布一年期LPR为3%，五年期LPR为3.5%，均与前值和预期一致。
上海黄金交易所黄金、白银 T+D 早盘上涨
快讯正文
黄金T+D早盘盘初涨3.11%报973.28元/克；白银T+D涨5.15%报16204元/千克。
韩国交易所启动 KOSPI 侧车机制，暂停程序化买入
快讯正文
韩国交易所启动侧车机制，暂停韩国综合指数程序化买入；同一早盘KOSPI此前涨幅扩大。
LME三个月期铜盘中下探后反弹，库存增加
快讯正文
LME三个月期铜盘中一度跌至8月3日以来最低，随后反弹；同时库存急剧增加，市场关注新奥尔良集中入库与关税决定。
Stripe 宣布与 OpenRouter 达成收购协议
快讯正文
Stripe宣布已与AI公司OpenRouter达成收购协议，交易条款未披露；此前有知情人士称交易价格超过70亿美元。
OpenAI 称 ChatGPT 注册、登录功能中断并修复中
快讯正文
OpenAI称ChatGPT.com注册、登录功能发生中断，正在修复；另有用户反馈平台出现故障。
日本7月出口同比增长23.2%，半导体设备出口增长49.1%
快讯正文
日本7月出口同比增长23.2%，进口同比增长27.8%，贸易逆差6345亿日元；半导体设备出口同比增长49.1%，石油进口额同比增长87.8%。
特朗普宣布对伊朗采取“史上最严厉”的经济制裁措施
快讯正文
特朗普称将对伊朗实施前所未有的经济制裁和孤立，并要求停止石油走私、互换额度、现金转账、船舶注册和空壳公司等活动；向伊朗提供救助的国家将面临经济后果。
科技要闻：三星代工价格、SK海力士回购与 CoWoS 供需
快讯正文
金十汇总称：据悉三星芯片代工价格最高上涨15%；CoWoS产能供不应求；SK海力士将买进40万亿韩元库库股；消息称三星目标9月完成1d nm DRAM研发。
扩大美债回购后亚洲股指期货走高
快讯正文
金十早盘综述称，日本、韩国和澳大利亚股指期货显示开盘上涨，市场关注财政部扩大回购能否压低债券收益率。
CME：美联储9月维持利率不变概率为67.3%
快讯正文
金十转述CME“美联储观察”：9月维持不变概率67.3%，累计加息25个基点概率32.7%；10月维持不变概率58.3%。
美国 CFTC 就 AI 算力期货征求公众意见
快讯正文
CFTC就算力期货合约公开征求意见；CME、洲际交易所等已宣布计划在获监管批准后推出相关合约。
特朗普再次敦促美联储降息
快讯正文
特朗普称美国利率成本过高；其表示每降低1个百分点利率相当于减少约6000亿美元成本。
国际油价19日上涨
快讯正文
纽约9月轻质原油期货收于85.83美元/桶，涨1.05%；10月布伦特原油收于91.62美元/桶，涨0.66%。
美联储工作人员：经济展望略显疲弱，通胀风险偏上行
快讯正文
工作人员预计下半年总体通胀回落、核心通胀小幅放缓；相较6月预测，经济活动展望略显疲弱，就业和实际GDP增速风险偏下行，通胀风险偏上行。
美联储会议纪要提及 AI 股票估值与国债波动风险
快讯正文
部分与会者关注AI基础设施融资脆弱性、高估值企业盈利预期下修引发资产重定价，以及美国国债价格波动对金融体系的影响。
美联储会议纪要未出现支持降息的观点
快讯正文
金十转述会议纪要称，纪要未提及支持降息的观点；市场因近期通胀降温和就业走弱而降低9月加息押注。
美联储会议纪要：若通胀未降温，许多官员认为有必要进一步收紧政策
快讯正文
会议纪要称，许多与会者认为若通胀无法降至2%目标，政策可能需要进一步收紧；数名政策制定者在7月会议上倾向加息。
民调涉及特朗普家族加密货币项目与政策影响观感
快讯正文
路透社/益普索民调转述称，63%的美国受访者认为特朗普及其家族通过加密货币项目获利超过10亿美元“不恰当”；48%的特朗普共和党支持者认为其商业交易会影响官方政策。
阿联酋宣布暂停与伊朗的贸易、商业及金融交易
快讯正文
阿联酋外交部称，因地区局势升级，已暂停与伊朗的一切贸易、商业及金融交易，直至另行通知。
美股周二收跌，半导体股走弱
快讯正文
道指跌约0.2%，标普500跌0.69%，纳指跌1.33%；闪迪、西部数据、美光、SK海力士跌幅约7%至9%，英伟达跌2%。
事实参考
以下为事实表、数据对照、账户细项与来源口径，默认折叠；需要核对数据时展开。
美股 / ETF / 公开文章事实
美股 / ETF / 公开行情
| 标的 | IBKR 当前价 | 较前交易日 | 盘后/收盘后 | 上一交易日收盘 | 今日常规收盘 |
|---|---|---|---|---|---|
MSFT | 484.80 | +0.66% | +0.10% | 481.63 | 484.31 |
NVDA | 219.38 | -0.16% | +0.84% | 219.74 | 217.56 |
MRVL | 241.33 | +11.73% | +1.71% | 216.00 | 237.27 |
GFS | 49.34 | -1.12% | +1.56% | 49.90 | 48.58 |
APLD | 28.70 | +0.67% | +1.66% | 28.51 | 28.23 |
USAR | 18.21 | -1.62% | +0.66% | 18.51 | 18.09 |
SOXX | 528.10 | -0.62% | +1.62% | 531.39 | 519.67 |
SOXL | 126.21 | -2.24% | +4.53% | 129.10 | 120.74 |
FTXL | 228.16 | -1.23% | +0.66% | 230.99 | 226.67 |
PSI | 141.04 | -3.60% | +1.10% | 146.31 | 139.50 |
DRAM | 57.39 | +4.16% | +4.08% | 55.10 | 55.14 |
KMEM | 18.82 | +4.04% | +3.46% | 18.09 | 18.19 |
VRT | 263.80 | -3.21% | +1.07% | 272.54 | 261.00 |
COHR | 292.58 | -4.52% | +1.78% | 306.43 | 287.47 |
CRCL | 80.85 | +12.71% | +2.88% | 71.73 | 78.59 |
SPCX | 139.40 | -2.75% | -0.18% | 143.34 | 139.65 |
GOOG | 342.40 | +0.33% | +0.20% | 341.28 | 341.70 |
NBIS | 230.02 | -7.41% | +2.73% | 248.43 | 223.90 |
PLTR | 174.89 | +1.95% | -0.17% | 171.54 | 175.19 |
XLV | 175.66 | +3.49% | -0.01% | 169.73 | 175.68 |
美股事实与文章索引
| 标的 | IBKR 当前价 | 较前交易日 | 盘后/收盘后 | 文章数 | 数据缺口 |
|---|---|---|---|---|---|
MSFT | 484.80 | +0.66% | +0.10% | 8 条 | - |
NVDA | 219.38 | -0.16% | +0.84% | 8 条 | - |
MRVL | 241.33 | +11.73% | +1.71% | 8 条 | - |
GFS | 49.34 | -1.12% | +1.56% | 8 条 | - |
APLD | 28.70 | +0.67% | +1.66% | 8 条 | - |
USAR | 18.21 | -1.62% | +0.66% | 8 条 | - |
SOXX | 528.10 | -0.62% | +1.62% | 8 条 | - |
SOXL | 126.21 | -2.24% | +4.53% | 8 条 | - |
FTXL | 228.16 | -1.23% | +0.66% | 8 条 | - |
PSI | 141.04 | -3.60% | +1.10% | 8 条 | - |
DRAM | 57.39 | +4.16% | +4.08% | 8 条 | - |
KMEM | 18.82 | +4.04% | +3.46% | 8 条 | - |
VRT | 263.80 | -3.21% | +1.07% | 8 条 | - |
COHR | 292.58 | -4.52% | +1.78% | 8 条 | - |
CRCL | 80.85 | +12.71% | +2.88% | 8 条 | - |
SPCX | 139.40 | -2.75% | -0.18% | 8 条 | - |
GOOG | 342.40 | +0.33% | +0.20% | 8 条 | - |
NBIS | 230.02 | -7.41% | +2.73% | 8 条 | - |
PLTR | 174.89 | +1.95% | -0.17% | 8 条 | - |
XLV | 175.66 | +3.49% | -0.01% | 8 条 | - |
美股事实摘要
- 报价事实：上涨 9 / 下跌 11 / 震荡 0；广度 45.00%；平均较前交易日 +0.56%。
- 公开新闻/财报讨论覆盖：20 / 20 个标的；新闻条目 160 条。
公开数据对照
| 标的 | IBKR 当前价 | K线收盘 | K线来源 | 差异 | 5D | 20D | K线行数 |
|---|---|---|---|---|---|---|---|
MSFT | 484.80 | 484.31 | Yahoo Finance chart API | +0.10% | -1.65% | +24.07% | 169 |
NVDA | 219.38 | 217.56 | Yahoo Finance chart API | +0.84% | -2.91% | +2.59% | 505 |
MRVL | 241.33 | 237.27 | Yahoo Finance chart API | +1.71% | +9.30% | +12.46% | 169 |
GFS | 49.34 | 48.58 | Yahoo Finance chart API | +1.56% | -8.65% | -16.94% | 169 |
APLD | 28.70 | 28.23 | Yahoo Finance chart API | +1.66% | -9.37% | -6.15% | 169 |
USAR | 18.21 | 18.09 | Yahoo Finance chart API | +0.66% | -1.74% | +14.35% | 169 |
SOXX | 528.10 | 519.67 | Yahoo Finance chart API | +1.62% | -4.93% | -6.45% | 290 |
SOXL | 126.21 | 120.74 | Yahoo Finance chart API | +4.53% | -15.07% | -25.00% | 169 |
FTXL | 228.16 | 226.67 | Yahoo Finance chart API | +0.66% | -4.46% | -6.60% | 290 |
PSI | 141.04 | 139.50 | Yahoo Finance chart API | +1.10% | -7.60% | -9.10% | 290 |
DRAM | 57.39 | 55.14 | Yahoo Finance chart API | +4.08% | +0.62% | -4.55% | 96 |
KMEM | 18.82 | 18.19 | Yahoo Finance chart API | +3.46% | +2.36% | -4.96% | 35 |
VRT | 263.80 | 261.00 | Yahoo Finance chart API | +1.07% | -9.49% | -13.34% | 505 |
COHR | 292.58 | 287.47 | Yahoo Finance chart API | +1.78% | -19.17% | -7.92% | 287 |
CRCL | 80.85 | 78.59 | Yahoo Finance chart API | +2.88% | +10.26% | +18.79% | 286 |
SPCX | 139.40 | 139.65 | Yahoo Finance chart API | -0.18% | -4.45% | +21.16% | 47 |
GOOG | 342.40 | 341.70 | Yahoo Finance chart API | +0.20% | -0.20% | -0.06% | 169 |
NBIS | 230.02 | 223.90 | Yahoo Finance chart API | +2.73% | -13.62% | +2.63% | 169 |
PLTR | 174.89 | 175.19 | Yahoo Finance chart API | -0.17% | +2.43% | +40.64% | 129 |
XLV | 175.66 | 175.68 | Yahoo Finance chart API | -0.01% | +4.30% | +10.19% | 287 |
期权链事实
观察标的：MSFT, NVDA, MRVL, GFS, APLD, USAR, SOXX, SOXL, FTXL, PSI, DRAM, KMEM, VRT, COHR, CRCL, SPCX, GOOG, SPY, QQQ, PLTR, NBIS, XLV
来源：Yahoo Finance 公开期权链
覆盖：21 / 22 个观察标的。
| 标的 | Yahoo ATM IV | IBKR ATM IV | 25Δ Skew(P-C) | Skew到期 | Greeks覆盖 | Put/Call Vol | Put/Call OI | Max Pain | 最大OI | 期限结构 | Vol/OI异常 | 大单数 | 新闻数 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MSFT | 27.08% | N/A | N/A | N/A | N/A | 0.42 | 0.53 | 465.00 | C 550.00 (53,800) / P 350.00 (12,353) | 8D 27.08% / 29D 26.16% / 57D 27.61% / 92D 31.51% | 8 | 5 | |
NVDA | 50.65% | N/A | N/A | N/A | N/A | 0.43 | 0.77 | 215.00 | C 180.00 (106,240) / P 180.00 (70,802) | 8D 50.65% / 29D 39.70% / 57D 39.32% / 92D 40.99% | 6 | 5 | |
MRVL | 103.10% | N/A | N/A | N/A | N/A | 0.39 | 1.23 | 215.00 | C 280.00 (12,790) / P 75.00 (11,298) | 8D 103.10% / 29D 80.96% / 57D 79.70% / 92D 77.88% | 4 | 5 | |
GFS | 59.81% | N/A | N/A | N/A | N/A | 0.52 | 0.68 | 55.00 | C 70.00 (18,455) / P 45.00 (4,626) | 1D 59.81% / 29D 57.06% / 57D 60.64% / 148D 64.37% | 0 | 0 | 5 |
APLD | 88.38% | N/A | N/A | N/A | N/A | 0.25 | 0.52 | 29.00 | C 60.00 (17,243) / P 25.00 (5,471) | 8D 88.38% / 29D 85.74% / 43D 86.33% / 57D 92.48% | 0 | 0 | 5 |
USAR | 86.72% | N/A | N/A | N/A | N/A | 0.63 | 0.75 | 18.00 | C 22.00 (14,230) / P 25.00 (9,150) | 8D 86.72% / 29D 86.57% / 43D 85.55% / 120D 89.97% | 0 | 0 | 5 |
SOXX | 47.76% | N/A | N/A | N/A | N/A | 1.39 | 0.88 | 535.00 | C 670.00 (12,376) / P 500.00 (6,225) | 8D 47.76% / 29D 44.18% / 57D 46.70% / 92D 47.45% | 7 | 5 | |
SOXL | 128.80% | N/A | N/A | N/A | N/A | 1.97 | 2.41 | 140.00 | C 425.00 (2,489) / P 80.00 (8,750) | 8D 128.80% / 29D 122.64% / 43D 122.33% / 92D 127.09% | 0 | 0 | 5 |
FTXL | 65.98% | N/A | N/A | N/A | N/A | 0.24 | 0.25 | 225.00 | C 280.00 (242) / P 280.00 (68) | 1D 65.98% / 29D 24.45% / 120D 51.18% / 211D 50.34% | 0 | 0 | 5 |
PSI | 57.96% | N/A | N/A | N/A | N/A | 0.35 | 0.21 | 145.00 | C 205.00 (1,150) / P 135.00 (62) | 1D 57.96% / 29D 55.41% / 92D 52.56% / 183D 59.55% | 0 | 0 | 5 |
DRAM | 71.53% | N/A | N/A | N/A | N/A | 0.38 | 0.57 | 58.00 | C 122.00 (44,159) / P 55.00 (37,801) | 8D 71.53% / 29D 70.17% / 57D 69.59% / 92D 72.20% | 3 | 0 | 5 |
VRT | 58.41% | N/A | N/A | N/A | N/A | 1.92 | 1.59 | 270.00 | C 270.00 (2,499) / P 185.00 (8,133) | 8D 58.41% / 29D 54.66% / 57D 57.02% / 92D 61.10% | 0 | 0 | 5 |
COHR | 78.91% | N/A | N/A | N/A | N/A | 1.16 | 1.33 | 325.00 | C 250.00 (2,183) / P 240.00 (2,544) | 8D 78.91% / 29D 75.56% / 57D 74.67% / 92D 80.07% | 3 | 0 | 5 |
CRCL | 84.06% | N/A | N/A | N/A | N/A | 0.36 | 0.78 | 70.00 | C 100.00 (10,465) / P 90.00 (7,046) | 8D 84.06% / 29D 82.39% / 57D 82.12% / 92D 84.08% | 1 | 0 | 5 |
SPCX | 64.50% | N/A | N/A | N/A | N/A | 0.66 | 1.19 | 130.00 | C 150.00 (34,877) / P 100.00 (56,095) | 8D 64.50% / 29D 62.22% / 57D 62.73% / 92D 65.47% | 8 | 5 | |
GOOG | 30.06% | N/A | N/A | N/A | N/A | 0.79 | 0.91 | 340.00 | C 365.00 (14,266) / P 330.00 (28,046) | 8D 30.06% / 29D 29.26% / 57D 30.71% / 92D 33.83% | 1 | 5 | |
SPY | 10.08% | N/A | N/A | N/A | N/A | 3.44 | 5.00 | 773.00 | C 790.00 (47,203) / P 500.00 (302,139) | 7D 10.08% / 29D 12.57% / 57D 13.41% / 92D 14.72% | 8 | 0 | |
QQQ | 18.32% | N/A | N/A | N/A | N/A | 1.12 | 1.20 | 728.00 | C 800.00 (58,561) / P 700.00 (91,279) | 7D 18.32% / 29D 19.54% / 57D 20.60% / 92D 22.00% | 7 | 0 | |
PLTR | 48.10% | N/A | N/A | N/A | N/A | 0.78 | 0.95 | 157.50 | C 135.00 (21,965) / P 120.00 (18,609) | 8D 48.10% / 29D 46.47% / 57D 47.48% / 92D 54.41% | 2 | 5 | |
NBIS | 96.68% | N/A | N/A | N/A | N/A | 0.89 | 1.40 | 240.00 | C 250.00 (6,327) / P 210.00 (10,574) | 8D 96.68% / 29D 91.90% / 57D 94.01% / 92D 98.47% | 8 | 5 | |
XLV | 21.75% | N/A | N/A | N/A | N/A | 0.32 | 2.02 | 161.00 | C 170.00 (13,284) / P 70.00 (47,532) | 8D 21.75% / 29D 21.90% / 57D 23.57% / 120D 20.55% | 2 | 0 | 5 |
最新大单 / 异常成交
大单活动只保留最近一次成功的 Yahoo 期权链快照，不是逐笔成交 tape。 当前显示：本次快照 Top 80。
| 观察时间 | 标的 | 合约 | 方向 | Strike | 到期 | Volume | OI | IV | Vol/OI | 估算权利金 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918C00717000 | call | 717.00 | 2026-09-18 | 26,798 | 448 | 20.87% | 59.82 | $44,404,286 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA261120C00140000 | call | 140.00 | 2026-11-20 | 5,040 | 5,389 | 70.22% | 0.94 | $40,672,800 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00415000 | call | 415.00 | 2026-08-28 | 5,442 | 2,219 | 64.31% | 2.45 | $37,549,800 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ261120P00880000 | put | 880.00 | 2026-11-20 | 1,680 | 0 | 23.34% | N/A | $27,499,920 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00425000 | call | 425.00 | 2026-08-28 | 3,009 | 957 | 56.34% | 3.14 | $17,820,803 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00435000 | call | 435.00 | 2026-08-28 | 3,387 | 1,673 | 48.36% | 2.02 | $16,596,300 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA261016P00220000 | put | 220.00 | 2026-10-16 | 11,763 | 56,490 | 36.66% | 0.21 | $16,262,348 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918C00725000 | call | 725.00 | 2026-09-18 | 12,856 | 14,290 | 19.92% | 0.90 | $15,793,596 |
| 2026-08-20 02:01:32.644Z | NBIS | NBIS261016P00270000 | put | 270.00 | 2026-10-16 | 2,282 | 3,412 | 90.84% | 0.67 | $14,399,420 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ261016C00360000 | call | 360.00 | 2026-10-16 | 400 | 400 | 91.69% | 1.00 | $14,328,400 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00390000 | call | 390.00 | 2026-08-28 | 1,500 | 600 | 82.32% | 2.50 | $14,088,750 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00400000 | call | 400.00 | 2026-08-28 | 1,390 | 569 | 75.02% | 2.44 | $11,672,525 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA260828C00225000 | call | 225.00 | 2026-08-28 | 28,787 | 19,195 | 51.70% | 1.50 | $11,658,735 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA260918C00220000 | call | 220.00 | 2026-09-18 | 12,109 | 46,095 | 40.88% | 0.26 | $10,898,100 |
| 2026-08-20 02:01:32.644Z | SPY | SPY261120P00715000 | put | 715.00 | 2026-11-20 | 13,132 | 7,247 | 17.88% | 1.81 | $10,387,412 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA261016C00220000 | call | 220.00 | 2026-10-16 | 8,034 | 86,566 | 41.97% | 0.09 | $10,383,945 |
| 2026-08-20 02:01:32.644Z | PLTR | PLTR261120P00330000 | put | 330.00 | 2026-11-20 | 536 | 325 | 174.46% | 1.65 | $9,783,340 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA260828C00220000 | call | 220.00 | 2026-08-28 | 15,949 | 20,445 | 51.84% | 0.78 | $9,489,655 |
| 2026-08-20 02:01:32.644Z | MRVL | MRVL260918C00280000 | call | 280.00 | 2026-09-18 | 10,056 | 12,790 | 84.02% | 0.79 | $9,075,540 |
| 2026-08-20 02:01:32.644Z | SPY | SPY261016P00725000 | put | 725.00 | 2026-10-16 | 16,962 | 5,079 | 16.92% | 3.34 | $8,947,455 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA260828C00145000 | call | 145.00 | 2026-08-28 | 1,201 | 124 | 183.74% | 9.69 | $8,671,220 |
| 2026-08-20 02:01:32.644Z | NBIS | NBIS260828C00200000 | call | 200.00 | 2026-08-28 | 2,882 | 406 | 104.69% | 7.10 | $8,350,595 |
| 2026-08-20 02:01:32.644Z | NBIS | NBIS260828C00205000 | call | 205.00 | 2026-08-28 | 3,340 | 80 | 100.20% | 41.75 | $8,333,300 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918P00720000 | put | 720.00 | 2026-09-18 | 5,061 | 11,966 | 17.61% | 0.42 | $8,325,345 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00420000 | call | 420.00 | 2026-08-28 | 1,285 | 512 | 61.91% | 2.51 | $8,233,638 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918C00730000 | call | 730.00 | 2026-09-18 | 8,170 | 19,838 | 19.42% | 0.41 | $8,157,745 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ261120P00800000 | put | 800.00 | 2026-11-20 | 914 | 1,075 | 14.64% | 0.85 | $7,694,509 |
| 2026-08-20 02:01:32.644Z | SPY | SPY261016P00770000 | put | 770.00 | 2026-10-16 | 5,017 | 6,414 | 12.15% | 0.78 | $7,683,536 |
| 2026-08-20 02:01:32.644Z | MRVL | MRVL260918C00120000 | call | 120.00 | 2026-09-18 | 639 | 5,181 | 119.73% | 0.12 | $7,525,823 |
| 2026-08-20 02:01:32.644Z | NBIS | NBIS260828C00185000 | call | 185.00 | 2026-08-28 | 1,826 | 117 | 105.42% | 15.61 | $7,482,035 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918P00770000 | put | 770.00 | 2026-09-18 | 6,965 | 16,602 | 11.63% | 0.42 | $7,445,585 |
| 2026-08-20 02:01:32.644Z | SPCX | SPCX260828C00140000 | call | 140.00 | 2026-08-28 | 13,095 | 3,961 | 65.36% | 3.31 | $7,267,725 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918C00720000 | call | 720.00 | 2026-09-18 | 4,742 | 20,450 | 20.50% | 0.23 | $7,060,838 |
| 2026-08-20 02:01:32.644Z | PLTR | PLTR261016C00080000 | call | 80.00 | 2026-10-16 | 710 | 569 | 109.57% | 1.25 | $6,810,675 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA261120C00230000 | call | 230.00 | 2026-11-20 | 5,219 | 20,342 | 41.61% | 0.26 | $6,745,558 |
| 2026-08-20 02:01:32.644Z | SPY | SPY261120P00680000 | put | 680.00 | 2026-11-20 | 13,440 | 17,542 | 21.31% | 0.77 | $6,538,560 |
| 2026-08-20 02:01:32.644Z | SPY | SPY261120C00740000 | call | 740.00 | 2026-11-20 | 1,299 | 1,849 | 20.87% | 0.70 | $6,137,126 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918P00680000 | put | 680.00 | 2026-09-18 | 11,227 | 25,597 | 22.39% | 0.44 | $5,944,697 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918P00705000 | put | 705.00 | 2026-09-18 | 5,464 | 9,611 | 19.38% | 0.57 | $5,873,800 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00395000 | call | 395.00 | 2026-08-28 | 636 | 216 | 80.42% | 2.94 | $5,660,400 |
| 2026-08-20 02:01:32.644Z | GOOG | GOOG260918P00330000 | put | 330.00 | 2026-09-18 | 9,540 | 28,046 | 28.15% | 0.34 | $5,533,200 |
| 2026-08-20 02:01:32.644Z | SOXX | SOXX260918P00500000 | put | 500.00 | 2026-09-18 | 3,315 | 6,225 | 45.27% | 0.53 | $5,420,025 |
| 2026-08-20 02:01:32.644Z | MRVL | MRVL260828C00230000 | call | 230.00 | 2026-08-28 | 2,846 | 3,773 | 103.37% | 0.75 | $5,414,515 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918P00760000 | put | 760.00 | 2026-09-18 | 7,420 | 48,758 | 12.83% | 0.15 | $5,375,790 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918P00733000 | put | 733.00 | 2026-09-18 | 18,645 | 2,661 | 16.46% | 7.01 | $5,285,858 |
| 2026-08-20 02:01:32.644Z | MRVL | MRVL260828C00250000 | call | 250.00 | 2026-08-28 | 4,903 | 2,527 | 104.40% | 1.94 | $5,074,605 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918P00725000 | put | 725.00 | 2026-09-18 | 2,682 | 9,960 | 17.06% | 0.27 | $5,060,934 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA261120P00215000 | put | 215.00 | 2026-11-20 | 3,358 | 9,394 | 38.64% | 0.36 | $5,020,210 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918P00690000 | put | 690.00 | 2026-09-18 | 7,109 | 37,021 | 21.17% | 0.19 | $4,979,855 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918C00275000 | call | 275.00 | 2026-09-18 | 112 | 49 | 157.86% | 2.29 | $4,953,816 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA260918C00120000 | call | 120.00 | 2026-09-18 | 502 | 2,897 | 116.26% | 0.17 | $4,937,170 |
| 2026-08-20 02:01:32.644Z | SOXX | SOXX260918P00520000 | put | 520.00 | 2026-09-18 | 2,008 | 2,741 | 43.15% | 0.73 | $4,929,640 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918C00470000 | call | 470.00 | 2026-09-18 | 163 | 174 | 86.96% | 0.94 | $4,896,765 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918P00730000 | put | 730.00 | 2026-09-18 | 18,941 | 55,334 | 16.86% | 0.34 | $4,886,778 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA261120C00210000 | call | 210.00 | 2026-11-20 | 2,154 | 11,778 | 44.06% | 0.18 | $4,830,345 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918P00700000 | put | 700.00 | 2026-09-18 | 5,144 | 91,279 | 20.01% | 0.06 | $4,801,924 |
| 2026-08-20 02:01:32.644Z | NBIS | NBIS260918P00210000 | put | 210.00 | 2026-09-18 | 2,951 | 10,574 | 90.64% | 0.28 | $4,765,865 |
| 2026-08-20 02:01:32.644Z | SPCX | SPCX260918C00130000 | call | 130.00 | 2026-09-18 | 3,057 | 15,106 | 64.56% | 0.20 | $4,738,350 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918C00770000 | call | 770.00 | 2026-09-18 | 3,943 | 15,467 | 13.26% | 0.25 | $4,410,246 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00380000 | call | 380.00 | 2026-08-28 | 420 | 162 | 96.29% | 2.59 | $4,373,250 |
| 2026-08-20 02:01:32.644Z | PLTR | PLTR260828C00175000 | call | 175.00 | 2026-08-28 | 8,031 | 4,336 | 48.83% | 1.85 | $4,316,663 |
| 2026-08-20 02:01:32.644Z | MRVL | MRVL260918C00180000 | call | 180.00 | 2026-09-18 | 701 | 1,955 | 86.11% | 0.36 | $4,249,813 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918P00740000 | put | 740.00 | 2026-09-18 | 11,745 | 18,833 | 15.48% | 0.62 | $4,169,475 |
| 2026-08-20 02:01:32.644Z | NBIS | NBIS260918C00250000 | call | 250.00 | 2026-09-18 | 2,913 | 6,327 | 93.07% | 0.46 | $4,136,460 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918P00715000 | put | 715.00 | 2026-09-18 | 2,889 | 11,432 | 18.20% | 0.25 | $4,124,048 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00385000 | call | 385.00 | 2026-08-28 | 411 | 161 | 92.04% | 2.55 | $4,074,038 |
| 2026-08-20 02:01:32.644Z | SPY | SPY261120C00775000 | call | 775.00 | 2026-11-20 | 1,842 | 5,422 | 15.99% | 0.34 | $4,047,795 |
| 2026-08-20 02:01:32.644Z | SPY | SPY261016P00680000 | put | 680.00 | 2026-10-16 | 17,053 | 25,584 | 22.15% | 0.67 | $4,024,508 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ261120C00480000 | call | 480.00 | 2026-11-20 | 164 | 81 | 56.47% | 2.02 | $3,970,932 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918C00300000 | call | 300.00 | 2026-09-18 | 83 | 712 | 144.43% | 0.12 | $3,899,631 |
| 2026-08-20 02:01:32.644Z | NVDA | NVDA260828C00232500 | call | 232.50 | 2026-08-28 | 17,908 | 28,315 | 52.05% | 0.63 | $3,868,128 |
| 2026-08-20 02:01:32.644Z | NBIS | NBIS260918P00220000 | put | 220.00 | 2026-09-18 | 1,839 | 4,132 | 90.06% | 0.45 | $3,843,510 |
| 2026-08-20 02:01:32.644Z | QQQ | QQQ260918P00695000 | put | 695.00 | 2026-09-18 | 4,562 | 16,372 | 20.57% | 0.28 | $3,686,096 |
| 2026-08-20 02:01:32.644Z | MRVL | MRVL260828C00240000 | call | 240.00 | 2026-08-28 | 2,615 | 4,598 | 103.14% | 0.57 | $3,680,613 |
| 2026-08-20 02:01:32.644Z | MSFT | MSFT260828C00430000 | call | 430.00 | 2026-08-28 | 664 | 253 | 46.70% | 2.62 | $3,569,000 |
| 2026-08-20 02:01:32.644Z | PLTR | PLTR261016C00075000 | call | 75.00 | 2026-10-16 | 350 | 363 | 114.60% | 0.96 | $3,528,875 |
| 2026-08-20 02:01:32.644Z | MRVL | MRVL260918C00250000 | call | 250.00 | 2026-09-18 | 2,013 | 10,465 | 83.24% | 0.19 | $3,487,523 |
| 2026-08-20 02:01:32.644Z | PLTR | PLTR261120P00400000 | put | 400.00 | 2026-11-20 | 137 | 0 | 0.00% | N/A | $3,451,441 |
| 2026-08-20 02:01:32.644Z | SPY | SPY261120C00730000 | call | 730.00 | 2026-11-20 | 626 | 798 | 22.14% | 0.78 | $3,430,480 |
| 2026-08-20 02:01:32.644Z | SPY | SPY260918P00750000 | put | 750.00 | 2026-09-18 | 6,826 | 31,621 | 14.12% | 0.22 | $3,419,826 |
技术指标事实
| 标的 | 类型 | Benchmark | 最新价 | Strength | 日线九转 | 1H 支撑 / 压力 | 4H 支撑 / 压力 | 1D 支撑 / 压力 | 数据限制 |
|---|---|---|---|---|---|---|---|---|---|
MSFT | 美股/ETF | SPY | 484.8100 | 8.59 | 低序列第6根 | 479.5527 (-1.08%；摆动低点/区间极值/布林下轨) / 485.0870 (+0.06%；摆动高点/MA5/MA10) | 482.6527 (-0.45%；摆动低点/MA10/MA5) / 489.4288 (+0.95%；MA60/MA20/布林中轨) | 464.1310 (-4.17%；MA20/布林中轨/摆动高点) / 487.7140 (+0.70%；MA5) | - |
NVDA | 美股/ETF | SPY | 218.8500 | -0.84 | 低序列第2根 | 218.5123 (-0.15%；摆动低点/区间极值/布林下轨) / 221.6945 (+1.30%；摆动高点/布林上轨/MA120) | 218.8370 (-0.01%；摆动低点/MA5) / 222.5144 (+1.67%；MA10/MA30/摆动高点) | 216.2000 (-0.63%；摆动低点) / 217.9200 (+0.17%；摆动低点) | - |
MRVL | 美股/ETF | SPY | 240.8100 | 12.68 | 高序列第1根 | 240.0120 (-0.33%；MA5/摆动高点) / 247.1000 (+2.61%；摆动高点/区间极值) | 240.1300 (-0.28%；摆动高点) / 242.3153 (+0.63%；布林上轨) | 237.0213 (-0.10%；MA60) / 244.0432 (+2.85%；摆动低点/布林上轨) | - |
GFS | 美股/ETF | SPY | 48.8500 | -16.08 | 低序列第2根 | 48.1537 (-1.43%；摆动低点/区间极值/布林下轨) / 49.1215 (+0.56%；MA10/MA5/摆动高点) | 48.0900 (-1.56%；摆动低点) / 49.1040 (+0.52%；MA5) | 48.0000 (-1.19%；摆动低点) / 51.6130 (+6.24%；MA20/布林中轨/MA10) | - |
APLD | 美股/ETF | SPY | 28.5600 | -13.73 | 低序列第2根 | 28.4764 (-0.29%；MA5/摆动高点/MA30) / 28.8300 (+0.95%；摆动高点) | 28.1083 (-1.58%；摆动低点/MA5) / 28.9728 (+1.45%；摆动低点/摆动高点/MA120) | 27.9700 (-0.92%；摆动低点) / 28.8668 (+2.26%；MA20/布林中轨/MA30) | - |
USAR | 美股/ETF | SPY | 18.2400 | -0.13 | 低序列第1根 | 18.2066 (-0.18%；摆动低点/MA5/MA10) / 18.4567 (+1.19%；MA20/布林中轨/摆动低点) | 18.0450 (-1.07%；摆动高点/摆动低点) / 18.2470 (+0.04%；摆动低点/MA5) | 17.9500 (-0.77%；摆动低点) / 18.7600 (+3.70%；MA10) | - |
SOXX | 美股/ETF | SPY | 524.7000 | -5.08 | 低序列第2根 | 524.2034 (-0.09%；MA10/MA5/摆动低点) / 534.5494 (+1.88%；摆动高点/布林上轨) | 523.1880 (-0.29%；摆动低点/MA5) / 531.6853 (+1.33%；摆动低点/摆动高点/MA60) | 516.4100 (-0.63%；摆动低点) / 522.2400 (+0.49%；摆动低点) | - |
SOXL | 美股/ETF | SPY | 123.8500 | -20.57 | 低序列第2根 | 123.7800 (-0.06%；摆动高点) / 124.8355 (+0.80%；MA20/布林中轨) | 122.4000 (-1.17%；摆动低点) / 123.9100 (+0.05%；MA5) | 120.7400 (0.00%；摆动低点) / 120.7400 (0.00%；摆动低点) | - |
FTXL | 美股/ETF | SPY | 226.6700 | -6.06 | 低序列第2根 | 225.3245 (-0.59%；摆动低点/区间极值/布林下轨) / 227.9393 (+0.56%；MA10/摆动低点/MA20) | 224.2824 (-1.05%；摆动低点/布林下轨) / 228.9583 (+1.01%；摆动低点/MA5/MA60) | 223.6500 (-1.33%；摆动低点) / 229.0580 (+1.05%；MA20/布林中轨/摆动低点) | - |
PSI | 美股/ETF | SPY | 140.8500 | -7.19 | 低序列第2根 | 140.2745 (-0.41%；MA5/MA10) / 141.4200 (+0.40%；摆动高点) | 138.9879 (-1.32%；摆动低点/布林下轨) / 142.9816 (+1.51%；摆动低点/MA5) | 139.2000 (-0.22%；摆动低点) / 141.7200 (+1.59%；摆动低点) | - |
DRAM | 美股/ETF | SPY | 55.8800 | -0.63 | 低序列第1根 | 55.5541 (-0.58%；MA10/MA20/布林中轨) / 56.7893 (+1.63%；摆动低点/布林上轨/摆动高点) | 55.2987 (-1.04%；MA60/MA5/摆动高点) / 56.5400 (+1.18%；摆动低点) | 54.6433 (-0.90%；MA30) / 55.3400 (+0.36%；摆动高点/摆动低点) | - |
KMEM | 美股/ETF | SPY | 18.8300 | N/A | 低序列第1根 | 18.5521 (-1.48%；MA5/摆动低点/MA30) / 18.8827 (+0.28%；布林上轨/MA60/摆动高点) | 18.5700 (-1.38%；摆动低点) / 18.8848 (+0.29%；MA30/MA20/布林中轨) | 18.0692 (-0.66%；MA30/摆动高点) / 18.2200 (+0.16%；摆动高点) | 1D 少于 60 根K线 |
VRT | 美股/ETF | SPY | 263.5000 | -12.56 | 低序列第2根 | 263.4703 (-0.01%；MA10/MA5/摆动高点) / 266.5940 (+1.17%；摆动高点/MA20/布林中轨) | 269.3793 (-0.08%；摆动低点/MA60) / 272.5500 (+1.10%；摆动低点/布林下轨) | 230.8672 (-11.55%；布林下轨) / 267.5200 (+2.50%；摆动低点) | - |
COHR | 美股/ETF | SPY | 292.0300 | -14.81 | 低序列第2根 | 290.1300 (-0.65%；摆动低点/MA5/MA10) / 296.4680 (+1.52%；摆动低点/MA20/布林中轨) | 281.8346 (-3.49%；摆动低点/摆动高点/布林下轨) / 294.4450 (+0.83%；摆动高点/MA5) | 255.1400 (-11.25%；摆动低点) / 304.8448 (+6.04%；摆动低点/MA30/MA20) | - |
CRCL | 美股/ETF | SPY | 80.4500 | 10.18 | 高序列第9根已完成，延续1根 | 79.9065 (-0.68%；MA10/MA5) / 81.2933 (+1.05%；摆动高点/区间极值) | 79.8241 (-0.78%；布林上轨) / 81.3300 (+1.09%；区间极值) | 77.6392 (-1.21%；布林上轨/摆动低点) / 87.3000 (+11.08%；摆动高点) | - |
SPCX | 美股/ETF | SPY | 139.3500 | N/A | 低序列第2根 | 137.1367 (-1.59%；摆动低点/布林下轨) / 139.6151 (+0.19%；摆动低点/MA5/MA10) | 136.2202 (-2.25%；摆动低点/布林下轨) / 139.7580 (+0.29%；摆动低点/摆动高点/MA5) | 137.6720 (-1.42%；MA10) / 142.1020 (+1.76%；MA5) | 1D 少于 60 根K线 |
GOOG | 美股/ETF | SPY | 341.7500 | -6.01 | 低序列第9根已完成，延续1根 | 340.5441 (-0.35%；摆动低点/区间极值/布林下轨) / 344.7861 (+0.89%；摆动低点/摆动高点/MA120) | 340.7822 (-0.28%；摆动低点/布林下轨/MA10) / 346.2876 (+1.33%；MA30/布林上轨/摆动高点) | 333.6900 (-2.34%；摆动低点) / 342.8687 (+0.34%；摆动低点/MA5/MA120) | - |
PLTR | 美股/ETF | SPY | 175.6200 | 21.63 | 低序列第1根 | 172.9947 (-1.49%；摆动高点/摆动低点/MA30) / 176.2578 (+0.36%；摆动高点/MA10/MA5) | 174.1782 (-0.82%；MA5/MA30/MA20) / 176.2800 (+0.38%；摆动高点) | 174.4660 (-0.41%；MA5) / 179.9867 (+2.74%；摆动高点/区间极值) | - |
NBIS | 美股/ETF | SPY | 228.3900 | 1.31 | 低序列第2根 | 226.0065 (-1.04%；MA10/MA5) / 232.5723 (+1.83%；摆动高点/MA20/布林中轨) | 224.5000 (-1.70%；摆动高点) / 230.1240 (+0.76%；摆动高点/MA5) | 211.9485 (-5.34%；MA20/布林中轨) / 225.0610 (+0.52%；MA60) | - |
XLV | 美股/ETF | SPY | 175.6800 | 8.56 | 高序列第2根 | 172.6938 (-1.70%；MA30/MA20/布林中轨) / 175.7622 (+0.05%；摆动低点/MA10/MA5) | 175.0582 (-0.35%；布林上轨) / 176.6000 (+0.52%；摆动高点/区间极值) | 172.6642 (-1.72%；布林上轨) / 176.6000 (+0.52%；区间极值) | - |
BTCUSDT | Crypto | BTCUSDT | 69,719.9000 | 0.00 | 高序列第4根 | 69,282.4550 (-0.63%；MA10/MA5) / 70,316.0667 (+0.86%；摆动高点/区间极值) | 69,125.7109 (-0.85%；布林上轨) / 70,450.0000 (+1.05%；摆动高点/区间极值) | 68,197.4651 (-2.18%；布林上轨/MA120) / 71,397.0000 (+2.41%；区间极值) | 自身为基准 |
ETHUSDT | Crypto | BTCUSDT | 2,267.4300 | 13.84 | 高序列第4根 | 2,259.3140 (-0.36%；MA5) / 2,336.8200 (+3.06%；摆动高点/区间极值) | 2,189.9086 (-3.42%；布林上轨) / 2,336.8200 (+3.06%；区间极值) | 2,151.8821 (-5.10%；布林上轨) / 2,336.8200 (+3.06%；区间极值) | - |
SOLUSDT | Crypto | BTCUSDT | 85.3300 | 5.06 | 高序列第3根 | 85.3060 (-0.03%；MA5) / 87.3000 (+2.31%；摆动高点/区间极值) | 84.0469 (-1.50%；布林上轨) / 87.3000 (+2.31%；区间极值) | 83.9600 (-1.61%；摆动高点) / 87.3000 (+2.31%；区间极值) | - |
账户、公开补充与来源
IBKR 账户与保证金
| --- |--- | | 已连接 |是 | | 持仓数 |已隐藏 | | 错误数 |0 |
| --- |--- |--- |--- | | 已隐藏 |AvailableFunds |已隐藏 |USD | | 已隐藏 |BuyingPower |已隐藏 |USD | | 已隐藏 |GrossPositionValue |已隐藏 |USD | | 已隐藏 |InitMarginReq |已隐藏 |USD | | 已隐藏 |MaintMarginReq |已隐藏 |USD |
持仓上下文
- 已隐藏
- 已隐藏
- 已隐藏
数据源列表
- Binance 合约市场数据
- IBKR 行情数据
- IBKR 账户与持仓数据
- Merkl 官方奖励数据
- Yahoo Finance 公开期权链
- Yahoo Finance 历史行情
- Yahoo Finance 新闻检索
- 金十数据快讯事实雷达